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Abbreviations 
Bgn   biglycan 
BMP   bone morphogenic protein 
BSA   bovine serum albumine 
CTGF   connective tissue growth factor 
Dcn   decorin 
ECM    extracellular matrix 
ERK    extracellular signal regulated kinase 
et al.   et alii 
FAK    focal adhesion kinase 
bFGF    basal fibroblast growth factor 
g    gramm 
GAG    glycosaminoglycan 
kDa    kilodalton 
kg   kilogram 
l    litre 
LDL   Low density Lipoprotein 
MAPK    mitogen activated protein kinase 
MI   myocardial infarction 
µl   micro-litres 
ml   milli-litre  
µM   micro-molar 
mM   mili-molar 
MMP    matrix metalloproteinase 
mRNA   messenger RNA 
NFκB   nuclear factor kappa β 
PARP   poly [Adenosine-diphosphate]-polymerase 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PDGF    platelet derived growth factor 
rpm   rotations per minute 
SMAD   mothers against decapentaplegic homolog 
SMURF  E2 ubiquitin ligase SMURF2 
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TAK1   transforming growth factor β associated kinase 1 
TEMED   N,N,N′,N′-Tetramethylethan-1,2-diamin 
TGF-β   transforming growth factor-β 
TGF-β RI/II  transforming growth factor-β receptor type I/II 
TLR   toll- like receptor 
TBS   tris buffered saline 
WT   wild-type
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1 Introduction 
1.1 Cardiac Remodelling 
 
Myocardial infarction (MI) occurs as the result of total occlusion of a pre-
atherosclerotic coronary artery and leads to ischemia characterized by necrosis 
of cardiomyocytes (1). This event is followed by continuous changes within the 
myocardium. Granulation of tissue and scar formation both come along with 
molecular, cellular and extracellular adaptations. Cardiac remodelling manifests 
as changes in left ventricle size, shape, wall thickness and function. The cellular 
and extracellular response leads to wall thinning, dilation and infarct expansion 
as well as inflammation and necrotic resorption. Once cardiomyocytes 
disappear in the infarct zone, fibroblasts accumulate to form a scar by 
extracellular matrix (ECM) remodelling. Remodelling is influenced by a variety of 
aspects like inflammatory response, growth factor secretion but also by 
hemodynamic load and pressure. Adverse or pathological remodelling leads to 
fibrosis dilation and the loss of heart function (2). ECM remodelling appears 
during all stages of infarct healing and scar formation. Remodelling is 
characterized by de novo synthesis and degradation of ECM (3). Cardiac 
remodelling is best investigated in response to injury after MI and has been 
described also in response to pressure overload, volume overload, 
cardiomyopathy, infection or cardiotoxic agents as well (2). 
 
 
1.1.1 Cardiac fibroblasts and their differentiation into 
myofibroblasts 
 
Cardiac fibroblasts are the main non-myocyte population in the heart. In the 
adult murine heart approximately 45 % of the non-myocytes                                                                                                      
are fibroblasts the other non-myocyte hearts are cells of the vasculature, 
endothelial and smooth muscle cells (4). Cardiac fibroblasts maintain the 
chemical and biomechanical responsiveness of the heart tissue and  preserve 
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the tissue structure via autocrine and paracrine action of secreted factors, cell-
cell interactions or cell-matrix interactions (5). Fibroblasts maintain ECM 
homeostasis and thereby tissue integrity. In cases of injury, fibroblasts start 
remodelling to restore cardiac tissue and function. If this restoration of a 
functional tissue fails, it results in heart failure (6). Fibroblasts differentiate into 
myofibroblasts in response to injury. These differentiated myofibroblasts are the 
key cell type that reorganizes ECM to adapt to injury (6). Myofibroblasts act 
upon paracrine and autocrine secreted signalling molecules. Activated 
myofibroblasts express both isoforms of the cyclo-oxigenase, the constitutively 
expressed COX1 and the inducible COX2, and are capable of prostaglandin 
secretion (7-11). 
 
Table 1-1 Myofibroblast secreted signalling mediators  
Cytokines/ 
Chemokines 
Growth 
Factors 
Inflammatory 
Mediators 
Neurotransmitters 
& Paracrine 
Mediators 
Receptors Adhesion Proteins 
IL-1β TGF-β PLA2 activating protein acetylcholine IL-1 ICAM-1 
IL-6 CSF1 PGE2 histamine IL-1Rα VCAM-1 
TNF-α GM-CSF prostacyclin serotonin TNF-αR NCAM 
IL-10 PDGF-AA HETES bradykinin IL-6R MCP-1 
IL-8 PDGF-BB PAF endothelin IL-8R α1β1-integrin 
MCP-1 bFGF NO ANF IL-4R CD18 
GRO-1α IGF-I & -II CO aldosterone IL-11R  
MIP-1α NGF H2O2, O- ANG II TGF-α/EGFR  
MIP-2 KGF   TGF-βR I & II  
RANTES HGF   PDGF-α & β  
ENA-78 SCF   c-kit  
    FGFR I & II  
    IGF-R  
    Thrombin R  
IL, Interleukin; TNF, tumor necrosis factor; TGF, transforming growth factor; MCP, monocyte 
chemoattractant protein; CSF, colony stimulating factor; GM-CSF, granulocyte/macrophage-
colony stimulating factor; PDGF, platelet derived growth factor; FGF, fibroblast growth factor; 
IGF, insulin-like growth factor; NGF, nerve growth factor; KGF, keratinocyte growth factor; HGF, 
hepatocyte growth factor, SCF, stem cell factor; MIP, macrophage inflammatory protein, 
RANTES, regulated upon activation of normal T-cell expressed and secreted; ENA, epithelial 
neutrophil activating peptide; PLA2, phospholipase A2; GRO, melanoma growth-stimulatory 
activity; HETES, hydroxyeicosatetraenoic acids; PAF, platelet activating factor; ANF, atrial 
natriuretic factor; PGE, prostaglandin E; EGF, endothelial growth factor; ICAM, intracellular 
adhesion molecule; VCAM, vascular cell adhesion molecule; NCAM, neural cell adhesion 
molecule; R,RI and RII receptor types (12)  
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Table 1-1 presents an overview on signalling molecules and receptors secreted 
and expressed by myofibroblast. This set of bioactive mediators clearly shows 
that myofibroblasts are highly active and able to influence a broad variety of 
other cell types.  
Myofibroblast exhibit clearly defined functions. Myofibroblasts become activated 
and proliferate in response to cytokines, chemokines, growth factors, ECM 
molecules and tension. Upon activation myofibroblasts secrete an increasing 
amount of ECM molecules and additional signalling molecules. The 
disappearance of myofibroblasts after tissue repair and scar formation is 
regulated by apoptosis (fig. 1-1) (13-17). 
TGF-β appears to be one of the most important mediators of myofibroblast 
differentiation, leading to the activated phenotype. In some tissues 
myofibroblasts have already been distinguished in activated myofibroblasts and 
transient myofibroblasts. The transient myofibroblast exhibits a stellate 
phenotype characterised by decreased proliferation (18,19) 
As myofibroblasts are not present in the healthy myocardium, the differentiation 
of cardiac fibroblasts into myofibroblasts is a crucial event in infarct healing (21). 
Compared to normal fibroblasts, myofibroblasts are more motile and show 
higher proliferative and ECM producing activity. Myofibroblast express 
contractile proteins  (22). Tissue contraction by myofibroblasts is a characteristic 
feature of the healing process. In the skin myofibroblasts undergo apoptosis 
after a normal status of a healthy re-established tissue is reached (23). After MI 
myofibroblasts will persist in the infarct area. The persistence of larger numbers 
of myofibroblasts in the heart could lead to fibrosis and thus to further 
impairment of cardiac function. Longer persistence of cardiac myofibroblasts 
might in part be explained by the mechanical load through heart contraction and 
relaxation. This shows that cardiac myofibroblasts have tissue specific 
characteristics (16,23). 
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Figure 1-1 Differentiation of fibroblast to myofibroblast 
Resident fibroblasts or fibrocytes differentiate into an active state through pro-inflammatory 
and/or pro-fibrotic stimulation, mechanical forces and ECM remodelling. Activated 
myofibroblasts secrete TGF-β as well as fibronectin fragment ED-A, both known to  induce 
further differentiation characterized by incorporation of α-smooth muscle actin  into stress fibres. 
Myofibroblasts are characterized by strong contractile abilities that are necessary for ECM 
remodelling. Once the tissue has achieved a functionally healed state, when stress releases and 
the tensile forces within the tissue reach a normal level, myofibroblasts undergo apoptosis and 
disappear. (Scheme adapted and modiefied from Hinz et al. (20)).  
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1.2 Small leucine-rich repeat proteoglycans: biglycan 
 
Biglycan is a class II small leucine-rich repeat proteoglycan (SLRP). The gene 
encoding for biglycan is located on the x-chromosome and is conserved in 
mammalian species. The biglycan gene (bgn) consists of 8 exons and the exon 
structure has no obvious relation to the structural domains of the core protein. 
The gene structure is identical to the homologous SLRP decorin in length and 
position.  
 
Figure 1-2 Schematic organization of biglycan proteoglycan 
The protein core is dominated by the twelve tandem leucine-rich repeats (green) which are 
flanked by cystein-clusters (turquoise). There are two glycosaminoglycan attachment sites for O-
linked glycans at the extreme amino terminus (lilac) and two more attachment sites for N-linked 
glycans near the c-terminal cystein-cluster. 
 
 
The complete conservation of intron and exon organization of biglycan and 
decorin indicates that they may have evolved from a common ancestor gene 
(24). On protein level biglycan shows a high homology to decorin, fibromodulin 
and asporin (9,10).The protein contains twelve tandem leucine-rich repeats and 
two glycosaminoglycan attachment sites at the extreme amino terminus. 
Biglycan is classified as a dermatan- or chondroitin-sulphate proteoglycan 
whereas in most connective tissues chondroitin-sulphate is modified to 
dermatan-sulphate. Biglycan is synthesized as a pro-peptide and cleaved by 
BMP1 to its mature form (25,26). Biglycan also exists in non-glycanated forms 
that accumulate with age (13,14). These non-glycanated forms of biglycan are 
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results of proteolysis within the amino terminal region of the core protein for 
example after cleavage by MMP13 (27). 
The functions of biglycan show a broad diversity and are cell type and tissue 
specific. 
 
 
1.2.1 Biglycan interacts with growth factors, surface complexes, 
receptors and ECM proteins 
 
Despite its structural functions biglycan  is involved in growth factor signalling by 
sequestering growth factors into the ECM (28). Biglycan is a ligand to receptors 
in innate immunity via binding to toll-like receptors 2 and 4 and promotes pro-
inflammatory signalling. Biglycan deficiency in mice causes a survival benefit in 
LPS- or zymosan-induced sepsis that is explained by lower concentrations of 
circulating TNF-α in blood and the reduced infiltration of mononuclear cells 
causing less end-organ damage. Furthermore, it has been shown that upon 
stimulation with LPS-induced pro-inflammatory factors, macrophages synthesize 
and secrete biglycan (29).  
Recently it was demonstrated that biglycan  acts as a ligand to CD44 and that it 
mediates leukocyte rolling by this interaction (30). CD44 is a cell surface 
receptor that is postulated to co-interact with TGF-β in myofibroblast 
differentiation (31). In addition biglycan is associated with the mechano-
transducing dystrophin protein complex that is carefully regulated in the heart 
and plays an important role in maintaining heart function. Biglycan has been 
shown to regulate the expression of complex components such as dystrobrevins 
and syntrophins as well as it seems to play a role in localization of the 
dystrophin associated protein complex (DAPC) in the sarcolemmal lipid rafts 
(32,33). Biglycan and decorin are key regulators of lateral assembly of collagen 
fibres. Deficiency of one or more SLRPs leads to abnormal collagen fibre 
diameters and disturbed lateral association of fibres (34,35). Both 
proteoglycans, biglycan and decorin, interact with tropoelastin. Especially 
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biglycan  binds the elastin core in elastic fibres (36).  It has also been shown 
that biglycan  can protect collagenous fibrils from cleavage by MMPs (37). 
 
 
1.2.2 TGF-β signalling and regulation 
 
TGF-β signalling has shown complex cross-talk to other signalling cascades, 
depending on genetic make-up, cell type, ECM environment and cellular origin. 
The canonical signalling by SMAD proteins involves different levels of regulatory 
mechanisms. The transcription of each component of the signalling pathway can 
be regulated. There is a variety of possible modifications like posttranscriptional 
regulation, posttranslational modifications, various interaction partners, as well 
as degradation by the proteasome (38). 
TGF-β influences other signalling molecules like CTGF or WISP1, as well as 
transcription factors like β-catenin and NFκB, too. The differences in cellular 
outcome reveals that not yet all possibilities of cross talk nor all members of the 
cascades might be known and that the function of each player is still not 
understood in total. 
Nevertheless TGF-β is the most important activator of myofibroblast 
differentiation. But it has been shown that other receptors like CD44 and 
signalling pathways like extracellular signal regulated kinase (ERK) are 
activated by TGF-β during differentiation (31,39). 
TGF-β is secreted in a latent form bound to a large multi-protein complex. 
Mature TGF-β can be sequestered by ECM molecules such as biglycan 
(28,31,39). TGF-β binds to TGF-β receptor type II (TGF-βRII) at the surface 
membrane which leads to recruitment of TGF-βRI. TGF-βRII then activates 
TGF-βRI by phosphorylation. This active complex recruits the receptor regulated 
r-SMADs (SMAD2 and 3). 
At the receptor complex r-SMADs become phosphorylated and thereby active. 
Phosphorylated r-SMADs can interact with common co-SMAD4 to build an 
active transcription factor-complex that translocates into the nucleus to induce 
transcription of TGF-responsive genes. Among these genes are cytoskeletal 
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components like α-SMA and adhesion molecules as well as various extracellular 
components like collagens and biglycan. Furthermore, active SMAD2 can 
interact with E2-ubiquitin ligase SMURF2, an interaction that leads to 
degradation of various transcription repressors like SnoN and c-SKI and thereby 
induces the transcription of further genes (40) . One of the responding genes is 
SMAD7 an inhibitory SMAD, localized in the nucleus. During TGF-β signalling 
SMAD7 leaves the nucleus, it interacts with SMURF2 in the cytosol and leads to 
degradation of TGF-βRI. This is a negative feedback loop to regulate TGF-β 
signalling (41). In addition SMAD7 interacts with the kinases TAK1, MKK3 and 
p38. Activation of this pathway induces phosphorylation of p53 leading to 
apoptosis. TAK1 also activates the transcription factor nuclear factor kappa B 
(NFκB), a pro-proliferative and pro-migratory factor. SMAD7 stabilizes β-catenin 
in the cytosol where it is localized at cadherin cell-cell adhesion sites. Upon 
TGF-β stimulation β-catenin accumulates in the cytosol as more adhesion sites 
are induced. This cytosolic accumulation of β-catenin is not only caused by 
induction of gene expression, it is also caused by a specific function of SMAD7. 
SMAD7 prevents ubiquitinylation and degradation of β-catenin. Accumulation of 
β-catenin can lead to active signalling as β-catenin translocates into the nucleus 
and induces transcription of genes associated with apoptosis. Furthermore 
SMAD7 interaction with β-catenin is required for TGF-β induced apoptosis (42-
44). 
The genes that are activated by TGF-β are predominantly encoding ECM 
molecules like collagens and the fibronectin ED-A fragment. Additionally TGF-β 
has been described to induce expression of plasminogen activator inhibitor 1 
(PAI-1) (45). Genes corresponding to proliferation are differentially regulated 
depending on cell type and molecular environment. While various cell types, 
including endothelial cells and epithelial cells, are inhibited in growth, 
mesenchymal cells like fibroblasts are stimulated (46). Upon stimulation with 
TGF-β r-SMADs become phosphorylated, which is the so called canonical 
pathway. On the one hand the smad2/3/4 complex activates expression of 
several genes for example, cycline-dependent kinase (CDK) inhibitors p15 and 
p21. 
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Figure 1-3 Simplified scheme of TGF-β signalling 
TGF-β interacts with the receptor complex and leads to recruitment of r-SMADs to the receptor 
complex where r-SMADs become phosphorylated. Phosphorylated r-SMADs can interact with 
co-SMAD4 to build an active transcription factor complex that translocates into the nucleus to 
induce transcription of TGF-responsive genes. Furthermore active SMAD2 can interact with E2-
ubiquitin ligase SMURF2, an interaction that leads to degradation of various transcription 
repressors like SnoN and c-SKI, thereby induces the transcription of further genes. One of the 
responding genes is SMAD7, an inhibitory SMAD, localized in the nucleus. Activated by TGF-β 
signalling SMAD7 leaves the nucleus. In the cytosol SMAD7 interacts with SMURF2 and leads 
to degradation of TGF-βRI receptor. This is a negative feedback loop to regulate TGF-β 
signalling. Furthermore SMAD7 interacts with TAK1, MKK3 and p38. Activation of this pathway 
induces phosphorylation of p53 leading to apoptosis. While TAK1 also activates the transcription 
factor NFκB. SMAD7 stabilizes β-catenin in the cytosol at cadherin adhesion sites. SMAD7 
interaction with β-catenin has been shown to be required for TGF-β induced apoptosis. 
 
On the other hand this complex of SMADs also represses the expression of 
genes such as cyclin-dependent kinases in coordinated function with 
transcription repressors like SnoN or Ski (38). Biglycan itself induces G1 arrest 
in pancreatic cancer cells by induction of p21 and p27 (47). These controversial 
effects of TGF-β demonstrate that its activity always depends on the cell type, 
environment and how the cell reads TGF-β signalling (48). 
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1.3 Biglycan and its role in cardiac system 
 
Biglycan is ubiquitously expressed in the healthy heart. It is expressed by 
cardiomyocytes and non-myocytes (fibroblasts) and is differentially regulated in 
response to pathological changes (49,50). It was reported that both SLRPs 
biglycan and decorin are up-regulated during infarct healing (51,52).  
 
 
Figure 1-4 biglycan accumulation within the infarct area 7 days after experimental MI 
Representative image shows an immunohistochemical staining for biglycan within the infarct 
zone 7 days after experimental myocardial infarction. Biglycan positive signal is stained as 
brown portion within the cross-section of the left ventricle from a WT mouse at 7 days after 
experimental myocardial infarction. 25 x magnification 
 
Biglycan-deficient male mice (bgn-/0) show increased mortality and impaired 
hemodynamic functions after experimental MI and a higher incidence for 
ventricular ruptures, as a stiff and hence fragile collagen scar is established in 
the absence of biglycan (52,53). Additionally it was shown that pro-hypertrophic 
and pro-fibrotic factors like WISP1 induce biglycan expression in vivo (49). It 
has been demonstrated in vitro that fibroblasts upon treatment with pro-fibrotic 
growth factors like TGF-β produce increasing amounts of ECM components, 
including SLRPs. Upon stimulation with pro-fibrotic growth factors the majority of 
fibroblast secreted SLRPs is biglycan (54).  
Biglycan is importantly relevant in the vascular system, where it influences the 
proliferation of vascular smooth muscle cells (55). But not only vascular smooth 
muscle cells are influenced by biglycan, it has been demonstrated that biglycan 
is essential for vessel stability by it’s presence in the adventitia. Because 
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biglycan deficiency in Balb/c mice leads to spontaneous aortic dissection and 
rupture, as the adventitia does not achieve normal functionality (56). In human 
aortic aneurysms a loss of biglycan has also been documented (57). 
Furthermore biglycan is up-regulated in pressure-overloaded rat hearts after 
aortic banding (58) which might contribute to biglycans function to stabilize the 
ECM. The biglycan expression increases in mesenchymal cells of the 
myocardial interstitium as well as in endothelial cells and smooth muscle cells of 
thickened coronary arteries as part of perivascular fibrosis. This indicates that 
biglycan contributes to both ventricular and vascular remodelling in response to 
pressure-overload (58). 
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1.4 Aim of Investigation 
 
Small leucine-rich repeat proteoglycans (SLRPs) are components of the ECM in 
every tissue, that interact with structural molecules like collagens, elastin, 
fibronectin and provides stability and integrity of the matrix. Investigations of the 
last years have shown that proteoglycans exhibit more functions than just 
decorating and filling the matrix: It has been revealed that biglycan and decorin 
are important for lateral association of collagen fibrils. Furthermore, SLRPs are 
not only sequestering growth factors within the ECM but also modulate growth 
factor and signalling molecule presentation to their receptors. In addition it was 
shown that SLRPs are themselves ligands for various receptors (29,30). 
Remodelling of ECM is a crucial process during hypertrophy and scar formation 
following ischemic myocardial infarction. About 70-80 % of non-myocytes in the 
heart are fibroblasts and these are the main source of scar forming molecules 
and thereby contribute to functionality of the tissue once the infarct has healed. 
Biglycan as well as collagens are induced in response to MI (52). Investigations 
of the role of biglycan for survival of mice after MI, showed that biglycan 
deficient mice die more frequently than WT-mice. As it turned out biglycan -
deficient mice show increased incidence for ventricular rupture, which was 
attributed to perturbed collagen network formation.  
 
The overall aim of the present thesis was to investigate the function of biglycan 
(bgn) regarding the phenotype of cardiac fibroblasts. For this purpose primary 
cardiac fibroblasts from bgn-/0-mice were compared to fibroblasts from wildtype 
mice (WT; CL57BL/6J) with respect to the following questions: 
 
(1) Do bgn-/0-fibroblasts exhibit differences in cellular morphology and 
phenotypical features?  
o Fibroblasts were analysed with respect to cell shape, proliferation 
and apoptosis.  
o The contractile responses of cardiac fibroblasts will be analyzed. 
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o Effects on the cytoskeleton, focal adhesions and ECM modifying 
enzymes will be determined? 
 
(2) What are the mechanisms of phenotypical differences between biglycan 
deficient and WT- fibroblasts?  
o Does lentiviral overexpression of murine biglycan rescue the 
biglycan knock out phenotype and does myofibroblast 
differentiation depend on biglycan expression? 
o Characterization of the TGF-β system will be performed and 
effects of neutralizing endogenous TGF-β will be analysed. 
Furthermore TGF-β canonical signalling will be addressed. 
 
(3) Is the described phenotype of relevance for post MI remodelling in vivo? 
o Myofibroblast phenotype of cardiac fibroblasts will be analyzed 
after experimental myocardial infarction in WT versus bgn-/0-mice. 
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2 Material and Methods 
 
This project includes molecular biological and biochemical procedures carried 
out in vitro by usage of a cell culture model of primary cardiac fibroblasts. To 
advance the relevance of the results translation to an in vivo model of 
myocardial infarction was included.  
 
 
2.1 Material and Substances 
 
In the following chapter, all materials and substances are listed with information 
of distributors. All substances were used at the highest analytical grade. 
 
2.1.1 Mice 
 
C57/BL6 mice were obtained by The Jackson Laboratory, Maine, USA, 
Tierversuchsanstalt, Heinrich-Heine University of Düsseldorf and Zentrales 
Tierlaboratorium, Universitätsklinikum Essen, University of Duisburg-Essen. 
Biglycan deficient (bgn-/0) mice were kindly supplied by Marian F. Young 
(Craniofacial and Skeletal Diseases Branch, National Institute of Dental and 
Craniofacial Research, NIH, Bethesda, Maryland, USA). Mice were fed with 
normal chow with food and water ad libitum and housed with a constant 12 h 
day- 12 h night-rhythm. 
 
2.1.2 Substances 
 
Phosphate-buffered saline (PBS), Dulbecco's Modified Eagle Medium (DMEM), 
fetal calf serum (FCS), penicillin/streptavidin, L-glutamin, Minimum Essential 
Media (MEM) and trypsin-EDTA solution were from GIBCO® supplied by 
Invitrogen, Darmstadt, Germany. Growth factors, DEAE-Sephacel and 
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chemicals were purchased from Sigma-Aldrich, Munich, Germany. [3H]-methyl-
thymidine was from Hartman Analytic, Braunschweig, Germany. Rotiszint® eco 
plus was delivered by Carl Roth, Karlsruhe, Germany. Pure-Col™ collagen 
solution for oil-supported collagen retraction assay was obtained from nutacon, 
Leimuiden, the Netherlands. Ascorbate was obtained from Caesar & Loretz 
GmbH, Hilden, Germany. 
 
Table 2-1 Buffers and Solutions 
Buffers and Solutions Ingredients 
ABC-Buffer 
0.60 g Tris 
1.33 g sodiumacetate x 3 H2O 
0.30 g NaCl 
ad 100 ml Aqua dest. 
BSA 1 mg/ml 
pH 8.0 
2-fold loading buffer 
150 mM Tris pH7 
4 % SDS 
20 % glycerol 
8 %  β-Mercaptoethanol 
Blocking buffer 2 mg/ml BSA in PBS 
Running buffer for SDS-PAGE 
25 mM Tris/HCL 
0.19 mM Glycine 
0.01 % SDS 
Stacking gel (5 %) 
0.5 M Tris pH 6.8 0.625 ml 
10 % SDS 50 µl 
dH2O 3.895 ml 
40 % Acrylamide 375 µl 
Temed 5 µl 
10 %  APS 50 µl 
Separating gel (10 %) 
1.5 M Tris pH 8.7 1.85 ml 
10 % SDS 75 µl 
dH2O 4.545 ml 
40 % Acrylamide 375 µl 
Temed 5 µl 
10 % APS 25 µl 
Transfer-buffer 
1 x Running Buffer 
20 % Methanol 
0.01 % SDS 
TBST 
100 mM Tris HCl 
1.5 mM NaCl  
0.1 % Tween 20 
pH7.4 
PBS 
137 mM NaCl 
2.7 mM KCl 
1.5 mM KH2PO4 
8.3 mM Na2HPO4   pH7.4 
Histoblock 2 % BSA 10 % FCS in 1 x PBS 
Blocking solution for endogenous peroxidases 3 % H2O2 in 1 x PBS 
Trisbuffer for immunohistochemistry 
6.07 g Tris 
ad 1 l Aqua dest. 
pH 7.6 
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Table 2-2 Substances, enzymes, kits and ready-to-use products 
Substances Distributor 
Phalloidin-FITC Sigma-Aldrich, Deisenhofen, 
Germany 
Chondroitinase ABC Sigma-Aldrich, Deisenhofen, 
Germany; and  Saikagaku, Tokio, 
Japan 
Quick Start Bradford Protein 
Assay 
BioRad; Munich, Germany 
SuperScript™ III First Strand 
cDNA Synthesis Kit 
Invitrogen, Karlsruhe, Germany 
 
SYBR Green® PCR Master Mix 
Applied  
Biosystems, Darmstadt, Germany 
TriReagent® Sigma-Aldrich, Deisenhofen, 
Germany 
Vectashield® Mounting 
Medium  
Vector Laboratories, CA, USA 
  
 
 
Table 2-3 Materials and Distributors 
Materials Distributor 
Protran™ nitrocellulose 
membrane for Protein Transfer 
0.2 µm 
Schleicher & Schuell / Whatmann (GB) 
Blot-paper Whatmann (GB) 
LabTek™ CC Chamber slides (8 
to 4 chambers) Nunc, Wiesbaden, Germany 
Super Frost™ Slides Menzel-Gläser, Braunschweig, GErmany 
 
 
Table 2-4 Primary antibodies and dilutions 
Primary andibodies Distributor Dilution 
Biglycan LF106, polyclonal Kindly provided by Larry Fisher (NIH, USA)  
1:1000 
 
Decorin LF113, polyclonal Kindly provided by Larry Fisher (NIH, USA)  
1:1000  
 
alpha-sm-actin, polyclonal  Abcam, Cambridge, UK 1:50 
Anti-fibronectin antibody Abcam, Cambridge, UK 1:100 
Anti-tropoelastin antibody Abcam, Cambridge, UK 1/250 
Anti-TGF-β1, -β2, -β3 
monoclonal neutralizing 
antibody 
R&D Systems, Inc. 
Minneapolis, MN, USA 0.5 µg/ml 
Mouse IgG1 Isotype 
Control 
R&D Systems, Inc. Minneapolis, 
MN, USA 0.5 µg/ml 
Anti-dystrophin antibody Abcam, Cambridge, UK 1:100 
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Rabbit polyclonal antisera to mouse biglycan  (LF-106 and LF 159) and mouse 
decorin (LF-113) were kindly provided by Larry Fisher (Matrix Biochemistry 
Section, CSDB, DIR, NIH, Bethesda, Maryland, USA) 
 
Table 2-5 Secondary antibodies 
Secondary antibodies Distributor Dilution 
IRDye 680 goat-anti-Rabbit 
IgG 
LI-COR Biosciences; Lincoln, 
NE, USA 
1:2500 
up to 
1:10000 
IRDye 800CW goat-anti-rabbit 
IgG 
IRDye 800CW goat-anti-
mouse IgG 
IRDye 680 goat-anti-mouse 
IgG 
goat-anti-rabbit IgG F(ab`)2 
Frag. Cy3-conjugated 
Sigma-Aldrich, Deisenhofen, 
Germany 1:600 
goat-anti-mouse IgG F(ab`)2 
Frag. Cy3-conjugated 
Sigma-Aldrich, Deisenhofen, 
Germany 1:600 
goat-anti-rat IgG, rhodamine-
red X conjugated, pre-
adsorbed, 
Dianova, Hamburg, Germany 1:400 
 
sheep-anti-rabbit Cy3 Sigma-Aldrich, Deisenhofen, Germany 1:200 
goat anti-rabbit horseradish-
peroxidase conjugated (HRP) Santa Cruz, USA 1:100 
 
 
Table 2-6 Laboratory Equipment 
Equipment Distributor 
spectralphotometer Nanodrop-1000 Peqlab, Erlangen, Germany 
rotary microtom  Leica RM 2255  Leica Microsystems, Wetzlar, Germany 
cryostat  Leica CM1850 Leica Microsystems, Wetzlar, Germany 
RT-qPCR Applied Biosystems 7300 Real-Time PCR System 
Applied Biosystems, 
Darmstadt, Germany 
   
Stereo-microscope Leica DM2000 Leica Microsystems, Wetzlar, Germany 
Mini-PROTEAN3 
electrophoresis 
chamber 
 
Mini-PROTEAN3 
Electrophoresis cell 
BioRad, Munich, 
Germany 
powersupply Power-Pac 200 +300 BioRad, Munich, 
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 Germany 
protein-transfer PerfectBlue Semi-Dry Elektroblotter 
Peqlab, Erlangen, 
Germany 
PCR-cycler Mastercycler Gradient Eppendorf, Hamburg, Germany 
realtime-PCR-cycler 
 
Applied Biosystems 7300 
Real-Time PCR System 
Applied Biosystems, 
Darmstadt,Germany 
centrifuge Centrifuge 5415R Eppendorf, Hamburg, Germany 
Odyssey Odyssey Near Infrared Imaging 
LI-COR Biosciences  
Lincoln, NE, USA 
 
Table 2-7 Real Time PCR Primer 
Gene primer-sequences 
gapdh 5’-TGGCAAAGTGGAGATTGTTGCC-3’ 5’-AAGATGGTGATGGGCTTCCCG-3’ 
α-sma  
5’-CAGGCATGGATGGCATCAATCAC-3’ 
5’-ACTCTAGCTGTGAAGTCAGTGTCG-3’ 
TGF-β 1 5 –CCGCAACAACGCCATCTATG-3’ 5’-CTCTGCACGGGACAGCAAT-3’ 
TGF-β receptor 
type II 
5’ -CAAGTCGGATGTGGAAATGG-3’ 
5’–AAATGTTTCAGTGGATGGATGG-3’ 
cd44 5’-AGG ATG ACT CCT TCT TTA TCC G-3’ 5’-CTT GAG TGT CCA GCT AAT TCG-3’ 
dystrophin 5’-GCCATAGCACGAGAAAAAGC-3’ 5’-CGGCTGTTCAGTTGTTCTGA-3’ 
syntrophin 5’-CCTCAAGAAGACAGGCAAGG-3’ 5’-GAGGTCCCTCCAGCAGAAT-3’ 
nos2 5’-GAAGAAAACCCCTTGTGCTG-3’ 5’-TTCTGTGCTGTCCCAGTGAG-3’ 
plod1 5’-GAGCCTTGGATGAAGTTGTG-3’ 5’-TAGTTGCCCAGGTAGTTCAG-3’ 
plod2 5’-AGTGGCAATTAATGGAAATGGG-3’ 5’-CTTGGGAGGGACATCTACTG-3’ 
tgm 1 5’-CCTCAGATGGATCTTCAATGGT-3’ 5’-CCATTGTGCCTTATATTGCAGAG-3’ 
tgm 2 5’-AAGAGCGAAGGGACATACTG-3’ 5’-TGCATCATACTTGGTACTCAGG-3’ 
 
 
Table 2-8 Sequencing primers 
Bgn-sequencing primer primer-sequences 
Exon 3 to Exon 1 5’-CCTGGTGGAGATTCCTCCCA-3’ 
Exon 4 to Exon 1 5’-AATGACATTTCTGAGCTTCG-3’ 
Exon 4 to Exon 8 5’-CTACGAATCCATGACAACCGT-3’ 
Exon 8 to End 5’-ACTGACCGCCTGGCCATCCAA-3’ 
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2.2 Methods 
2.2.1 Mice 
 
All procedures were performed in accordance with the AAALAC guidelines and 
Guide for the Care and Use of Laboratory Animals (Department of Health and 
Human Services, National Institutes of Health, Publication No. 86-23) and were 
approved by the ethical and research board of the University of Duisburg-Essen 
and the county of Essen. 
 
 
2.2.2 Isolation of primary murine cardiac fibroblasts 
 
Mice at the age of 4 up to 8 weeks were used for isolation of murine fibroblasts. 
Mice were euthanized by CO2 inhalation. Skin was removed and the chest was 
opened with sterile instruments. The heart was freed from pericardium and atria 
were removed. Ventricles and septum were transferred into sterile pre-warmed 
phosphate buffered saline (PBS) immediately. Hearts were washed twice in 
sterile pre-warmed PBS and cut into small pieces. Heart pieces were explanted 
into six-well culture plates using cardiomyocyte-plating medium containing 60 % 
FCS and 8 ng/ml basal fibroblast growth factor (bFGF). Culture plates were pre-
coated with 5 µg collagen type I /well. After 24 h at 37°C the plating medium 
was changed to DMEM containing 20 % FCS and 8 ng/ml bFGF. The medium 
was changed every second day for a period of two weeks. Afterwards 
fibroblasts were washed twice with PBS and treated with Trypsin for ten minutes 
at 37°C and separated from the heart pieces. Two da ys later the medium was 
changed to DMEM containing 10 % FCS and cells were used for experiments 
after achieving confluence. Only the first three passages of fibroblasts were 
used. 
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2.2.3 Cell growth and proliferation assays 
 
For cell growth experiments cells were treated with trypsin and counted in a 
hematocytometer upon addition of trypan blue to differentiate viable from dead 
cells. 
For assaying proliferation, the incorporation of [3H]-methyl-thymidine into new 
synthesised DNA was measured. Fibroblasts were plated at 5000 cells /cm² and 
either serum depleted or treated with media containing 2 or 5 % FCS. After the 
desired incubation time (24-48 h) the fibroblasts were washed with PBS and 
lysed by treatment with perchloracid and 1M NaOH for 45 min at 37°C. These 
lysates were analysed after addition of Rotiszint® eco plus in a scintillation 
counter. 
 
All experiments including stimulations were performed in DMEM-media 
containing at least 2 % FCS because bgn-/0-fibroblasts showed to be very 
sensitive towards serum depletion. Fibroblasts were assayed without previous 
serum depletion. Fibroblasts were synchronized by means of the plating 
procedure using trypsin for 10 min at RT, and resolving pelleted cells in DMEM 
containing 2 % FCS and plating a defined cell density by counting cells using a 
hematocytometer. 
 
 
2.2.4 Proliferation on cell-derived ECM from WT- or bgn-/0-
fibroblasts 
 
To determine influence of extracellular matrix (ECM) on proliferation cells were 
plated on cell culture plates and fed with DMEM containing 10 % FCS and 56 
µg/ml ascorbate to stimulate collagen production. After a feeding period of 20 
days, ECM was visible on the plate macroscopically. Cells were washed twice 
with PBS and lysed by 30 min incubation at RT using 2.5 µM 
ammoniumhydroxide. After lysis of the cells, the ECM was washed three times 
with sterile distilled water and stored at 4°C over  night. 
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Fibroblasts were plated on these ECM at a density of 103 cells per cm². The 
cells were allowed to settle and grow for 48 h. Afterwards cells were trypsin 
treated and counted as described above. 
 
 
2.2.5 Immunocytochemistry 
 
To assess morphological differences and determine states of differentiation 
fibroblasts were plated on LabTek cell culture micro slides plus minus the 
indicated stimuli. After incubation under standard conditions the cells where 
washed and fixed by 3.7 % saline-phosphate-buffered paraformaldehyde for 20 
min at RT. Afterwards the cells were incubated with the primary antibody in the 
recommended dilution for one hour at RT and washed again five times before 
the fluorochrome conjugated secondary antibody was added for one hour at RT. 
Cells were washed again to remove unbound antibody. Afterwards nuclei were 
stained by DNA binding HOECHST Dye (1:10000) for 5 min in the dark and 
embedded with Vectashield Mounting Medium. 
 
 
2.2.6 Oil supported collagen Retraction Assay 
 
Oil-supported collagen gel retraction assay was performed as described by 
Vernon and Gooden (59). This assay visualizes the abilities of cells to contract 
collagen matrices that are free of adhesion. Trypsin treated cells were mixed 
with PureCol collagen solution, 10 x DMEM saturated with Na2CO3, thus 
achieving a total concentration of 1.25 mg collagen per gel. Each gel contained 
15 x 103 cells.  12-well cell culture plates were prepared with 1.4 ml sterile 
mineral oil and a polyethylene (PE) ring and a Teflon® disk that secured the 
adhesion-free polymerization of collagen gels. The cell suspension was pipeted 
into the inner circle of the PE ring. To expand the gel to fill out the whole inner 
Material and Methods 
 
 
 
30
ring, the same volume of mineral oil was removed. Gels were polymerized for 2 
h at 37°C and 5 % CO 2. 
After incubation period of 24 h gel images were recorded under dark field 
illumination and analysed by NIH freeware ImageJ. Contraction was calculated 
as percentage of unpopulated control collagen gels. 
 
 
2.2.7 Protein Analysis 
 
To analyse protein expression and the phosphorylation status of signal-
transducing proteins, fibroblasts were lysed by 10 min incubation in HIDE-buffer 
containing protease and phosphatase inhibitors at 4°C and rigid scratching of 
cell culture dishes. Lysates were mixed with SDS-containing 2 fold loading 
buffer and run on 10 % polyacrylamide-SDS-gels, afterwards the proteins were 
transferred onto nitrocellulose membrane by electroblotting for 2 h at 1000 mA. 
Membranes were blocked in 2 % BSA/TBST for 1 h at RT and incubated in 
primary antibody-solution overnight. Removal of unbound primary antibody was 
achieved by repeated washing with TBST and followed by one hour of 
incubation in a solution containing the appropriate near-infrared- fluorochrome 
conjugated secondary antibody. 
The resulting fluorescent signal was detected with Odyssey Near Infrared 
System (Licor) 
 
 
2.2.8 Protein concentration 
 
For normalisation of proliferation assay and western blots the protein 
concentration of samples was measured via Bradford assay. Therefore 5 µl of 
each sample was mixed with 200 µl of Bradford Reagent (BioRAD) and 
absorption was measured with a plate reader at 595 nm. Concentration was 
calculated by standard curve of BSA. 
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2.2.9 Proteoglycan isolation from culture supernatants 
 
Proteoglycans were isolated according to standard procedures (60). Equal 
volumes of conditioned medium were collected and applied to Sephacel® -
DEAE-chromatography. Proteoglycans were eluted from the column with 3 M 
NaCl containing urea DEAE-buffer. The samples were precipitated three times 
in a row by 96 % ethanol containing 1.3 % potassium acetate in order to remove 
urea and salt. Salt free pellets were resuspended in a 20 µl of distilled water and 
digested with chondroitinase ABC for 3 h at 37°C, t o remove glycosaminoglycan 
chains from the core proteins of the proteoglycans. One third of the digestions 
were analysed by 10 % SDS-PAGE followed by standard western-blot 
procedure. 
 
 
2.2.10 RNA-extraction and quantitative Real-Time RT-PCR 
 
Total RNA was extracted from cell cultures using TRIzol® reagent (Invitrogen, 
Carlsbad, CA) according to the manufacturer’s instructions. Quality and 
concentration were determined using the NanoDrop® ND-100 (Wilmington, DE) 
spectrophotometer. The synthesis of cDNA by reverse transcriptase (RT) using 
random hexamer primers was performed with 1µg of total RNA using the  
quantitect reverse transcription kit (Qiagen, Hilden). 
Relative quantitation of mRNA expression levels were determined by qPCR with 
ABI 7300 real time system (Applied Biosystems, Darmstadt) using  Platinum 
SYBR green qPCR SuperMix-UDG kit (Invitrogen, Karlsruhe). The reaction 
volume of 20 µl contained 10 µl of Platinum SYBR green qPCR SuperMix-UDG, 
5 µl cDNA and 2.5 µl of each primer with a final concentration of 10 pmol for 
every primer. The glyceraldehyde- 3-phosphate dehydrogenase (gapdh) gene is 
constitutively expressed and was chosen as the endogenous control. The PCR 
amplification was performed at initially 50°C for 2  min, followed by 95°C for 2 
min and 40 cycles at 95°C for 30 s and terminated b y 60 °C for 30 s. During the 
last steps, a temperature gradient between 95°C and  60°C was created for the 
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analysis of the DNA dissociation curves. These dissociation curves can be used 
to monitor the PCR quality. The expression of each target gene was calculated 
in relation to the housekeeping gene, GAPDH, using the 2-∆∆Ct method as 
described before (61). 
 
 
2.2.11 Lentiviral overexpression of biglycan 
 
Briefly, cDNA of murine biglycan was obtained by RT-PCR using the whole RNA 
extracts from C57BL/6J WT mouse hearts. Amplification was achieved by using 
the following primers XhoI-mBGN-F 5'-
CTCGAGATGTGTCCCCTGTGGCTACTC-3' and EcoRI-mBGN-R 5'-
GAATTCCTACTTCTTATAATTTCCAAA-3'. The cDNA was cloned into the 
pCL1mcs vector using XhoI and EcoRI restriction sites. The production of 
lentivirus, harvest of recombinant lentiviral particles, and transduction of primary 
murine cardiac fibroblasts were performed as previously described (61). In this 
lentiviral vector, the CMV promoter drives the overexpression of biglycan. The 
pCL1 vector expressing only EGFP was used as mock control. Cells were used 
at day seven after transfection. For transfection cells were incubated with 
viruses at a dilution 1:20 for 24 h. 
The biglycan overexpression vector was sequenced to exclude any point 
mutations, especially in the extreme N-terminus where the GAG-chains would 
be attached to the core protein. For sequencing 100 ng of vector DNA were 
used. Sequencing was performed at GATC Biotech (Konstanz, Germany) and 
primers are presented in table 2-8). 
 
 
2.2.12 Experimental myocardial infarction 
 
At the age of 12 weeks WT- and bgn-/0-mice were anesthetized by i.p. injection 
of pentobarbital (100 mg/kg). A 2 cm long PE-90 catheter attached to the hub of 
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a needle was inserted into the trachea. In order to numb the throat and reduce 
gag reflex a drop of 1 % lidocaine was put on the tip of the tube. Mice were 
subjected to permanent left anterior descending artery (LAD)-occlusion followed 
by recovery for 3, 7 or 21 days. Infarcted left ventricles were freed from right 
ventricle tissue. RNA was isolated from a 1 mm thick section of the apex cordis. 
Hearts were immediately placed in cryomolds filled with OCT-Medium and 
frozen in liquid isopentan at 40°C without pre-fixa tion. All procedures were 
carried out as recently described in detail (62). 
 
 
2.2.13 Cryomicrotomy and immunohistochemistry 
 
Cross-sections of infracted left ventricles were prepared from un-fixed tissue. 
Cryomolds were stored at -80°C and brought to -25°C  two hours before 
sectioning. Sections were cut at -25°C at a thickne ss of 10 µm using a Leica 
cryostat. Frozen sections were allowed to acclimate to room temperature for two 
hours before staining. 
Sections were fixed for ten minutes in absolute ethanol at 4°C and rehydrated 
by 5 min in 70° ethanol at 4°C. Sections were washe d with PBS three times and 
incubated for 1 h at RT in histoblock. Incubation with primary antibody followed 
at 4°C over night. Primary antibody was removed by three times washing with 
PBS. Blocking of endogenous peroxidases was carried out in 3 % H2O2 in PBS 
for 20 min at RT. Secondary antibody was pipetted on every section and 
incubated for 1 hour at RT. Excess antibody was removed by washing with 
PBS. Adjusting the pH was achieved with trisbuffer for 10 min at RT. 
Detection with DAB solution was performed for 10 min at RT. Counter staining 
of nuclei was performed with Mayer’s Hematoxylin. 
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2.2.14 Statistical Analysis 
 
Quantitative results are presented as mean values plus minus the standard 
error of the mean (SEM). Data sets were compared by unpaired student’s T-
test, when only two groups of values were compared. For analysis of two groups 
under two or more conditions two way ANOWA had been applied to the data 
using the software PRISM Graphpad 4.0. Over all a p-value below 0.05 was 
considered as statistically significant. The statistical significance between WT 
and bgn-/0 is signatured by asterisk (*) while statistical significance between 
treatment within one group or genotype is signatured by hash key (#).
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3 Results 
 
During cardiac remodelling fibroblasts, which represent 70 % of the non-
myocyte cells within the myocardium, proliferate and secrete high amounts of 
ECM (ECM) to adapt to physiological challenges such as hypertension, 
myocardial infarction and inflammation (6). Biglycan-deficiency in mice leads to 
a higher incidence of ventricular rupture following experimental myocardial 
infarction and a dramatic increase in mortality of the bgn-/0-mice. 
Cardiac remodelling post infarction is a crucial process characterized by ECM 
production, cross linkage and degradation, thus leading to a stable scar tissue. 
As this healing process, mainly accomplished by myofibroblasts, is disturbed in 
bgn-/0-mice, it may be hypothesised that cardiac fibroblasts and their 
differentiation into myofibroblasts are influenced by the genetic knock out of 
biglycan. To explore these questions, isolated fibroblasts from either WT-mice 
or biglycan deficient mice were analysed ex vivo in explant cultures. 
 
 
3.1 Morphology of bgn-/0-fibroblasts revealed a distinct phenotype   
 
Fibroblasts from WT-explants grew out of explants during the first week. In 
comparison biglycan deficient (bgn-/0) -fibroblasts grew out already during the 
first three days after explantation. Fibroblasts were separated from explants by 
passaging and visualized by microscopy. The morphologies of the two different 
genotypes were of distinct differences. Bgn-/0-fibroblasts were smaller and had a 
round cell body with many lamelopodia, giving them a spider like shape, 
compared to WT-fibroblasts which were flat, evenly shaped and showed broad 
and fewer filopodia (figure 3-1).  
By measuring the cell-area from 50 cells per isolation, it became obvious that 
bgn-/0-fibroblasts were significantly smaller than the WT-fibroblasts (fig. 3-2). 
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Figure 3-1 Morphologic differences of bgn-/0-fibroblasts from WT-fibroblasts 
Microscopic images of WT- (A, B) and a bgn-/0-fibroblasts (C, D) taken at 200 (A, C) and 400 x 
magnification. (B, D) show smaller cell size of bgn-/0-fibroblasts exhibit smaller and more 
dynamic shape compared to WT. 
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Figure 3-2 Cell size of bgn-/0-fibroblasts is reduced in comparison to WT-fibroblasts 
50 cells of three independent explant cultures were documented. The cell size was determined. 
WT-fibroblasts (white bar) were significantly larger than bgn-/0-fibroblasts (black bar). means ± 
SEM; n=3 *; p<0.05 
 
The secretion of proteoglycans into conditioned media of the primary cardiac 
fibroblasts was analysed at 24 and 48 hours (figure 3-3). The results showed 
that media taken from bgn-/0-fibroblasts did not contain biglycan protein.  
Results 
 
 
 
37
Surprisingly, the media taken from bgn-/0-fibroblasts contained less decorin 
compared to the WT cell media. This outcome demonstrated that bgn-/0 -
fibroblasts do not compensate the lack of biglycan by over expressing decorin. 
 
 
Figure 3-3 Representative western blots of proteoglycans secreted by WT- and bgn-/0-
fibroblasts during 24 and 48 h 
Representative western blots of DEAE-isolated chondroitinase ABC digested proteoglycans 
from 1 ml conditioned cell culture supernatants, detected with anti-decorin LF113 (upper panel) 
and anti-biglycan LF106. Alternating order of WT and bgn-/0 samples taken from two 
independent explant-cultures of each genotype. This control experiment shows signals for 
biglycan only in lanes with media conditioned by WT-fibroblast. 
 
Additionally it was shown that bgn-/0-fibroblasts keep a comparable or even 
lower expression level of decorin even after 48 hour in culture. 
 
 
3.2 Bgn-/0-fibroblasts showed a pro-proliferative phenotype 
 
Cell numbers were determined after separating cells from heart pieces 14 days 
after explantation. During this time explants were treated with 8 ng/ml basal 
fibroblast growth factor (bFGF), while medium was refreshed every second day. 
The number of bgn-/0 cells was 1.8 fold higher than cell numbers from WT hearts 
(fig. 3-4). 
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Figure 3-4 Outgrowth from bgn-/0-hearts was significantly higher  
Fibroblasts cultured in 20% serum containing DMEM in the presence of 8 ng/ml of basal 
fibroblast growth factor for 14 days. Fibroblasts were then trypsin treated and counted in a 
hematocytometer (WT white bar; bgn-/0 black bar). mean ± SEM; n = 5;*, p<0.05 
 
In order to find out whether the increased cell numbers were due to enhanced 
proliferation of biglycan-/0-fibroblasts, several assays to analyse proliferative 
responses of fibroblasts were performed. 
According to standard proliferation assay protocols, cells have to be 
synchronized by serum depletion for 24 up to 48 hours before stimulation. But 
serum depletion led to a total loss of bgn-/0-fibroblast proliferation. Even the 
following stimulation with either PDGF-BB or 10 % FCS could not restore 
proliferation in bgn-/0-fibroblasts as shown in fig. 3-5.  
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Figure 3-5 Serum-depletion irreversibly abolished proliferation benefit of bgn-/0-
fibroblasts. 
Fibroblasts were serum depleted for 24 hours followed by additional starving or treatment with 
either 10 ng/ml PDGF-BB or 10 % FCS for another 24 hours. Afterwards [H³]-thymidine 
incorporation was measured in a scintillation counter (Beckmann Coulter). Protein concentration 
of cell lysates was measured by Bradford assay for normalization. mean ± SEM; n = 5;*, p<0.05 
 
Bgn-/0-fibroblasts were highly sensitive to serum depletion in cell culture. 
Therefore, serum depletion was avoided as synchronising method in the 
following experiments. Due to the problems of bgn-/0-fibroblasts to survive under 
conditions of serum depletion, cells were routinely analysed at 12, 24 or 48 h 
after plating, assuming that plating is a synchronising process as well. 
[³H]-thymidine incorporation and cell counting experiments were performed to 
analyse proliferative responses of fibroblasts from bgn-/0-mice in comparison to 
WT-fibroblasts. Bgn-/0-fibroblasts showed increased proliferation under standard 
conditions independent of high or normal serum conditions, as long as the 
serum concentration was above 2 % serum. The proliferation benefit was 
determined by cell counting at 48 and 72 hours after plating (Figure 3-6). It was 
shown that the number of bgn-/0-fibroblast was 1.7 fold higher than proliferation 
of WT-fibroblasts at both time points. 
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Figure 3-6 Growth of bgn-/0-fibroblasts was significantly increased over time in 
comparison to WT-fibroblasts. 
Fibroblasts were plated and grown in 10 % serum. Fibroblasts were trypsin treated and counted 
after 48 and 72 h. Data represents independent experiments performed in quadruplets. mean ± 
SEM; n = 4 and 6; *, p<0.05;  ***,p<0.001 
 
Determining cell numbers is a basal method, which does not exclude that the 
changes in cell numbers are due to differences in proliferation or survival. 
Therefore DNA-synthesis of WT- and bgn-/0-fibroblasts was compared after 24 h 
in 20 % serum by [3H]-thymidine incorporation. 
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Figure 3-7 DNA synthesis measured by [³H]-thymidine incorporation was increased in 
bgn-/0-fibroblasts 
DNA synthesis was measured by [3H]-thymidine incorporation 24 h after plating cells in 20 % 
DMEM. Experiments were performed in triplicates. mean ± SEM; n = 4;*, p<0.05 
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3.2.1 Proliferation on cell-derived ECM from either WT- or bgn-/0-
fibroblasts 
 
To investigate if the proliferation benefit of bgn-/0-fibroblasts was attributed to the 
lack of biglycan in the extracellular matrix, a proliferation assay using cell-
derived ECM as growth substrate was performed. For this purpose, fibroblasts 
from WT- and bgn-/0-mice were treated with 56 µg/ml ascorbate, which is 
described to achieve an increased production of collagen. After a feeding period 
of 20 days with refreshing the ascorbate-containing medium every second day, 
the ECM was visible macroscopically. Afterwards ECM-producing cells were 
lysed with ammoniumhydroxide and cell debris was removed by washing with 
distilled water. ECMs were stored at 4°C for 24 h. The prepared ECM was 
repopulated with freshly isolated cells for 48 h. 
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Figure 3-8 ECM derived from bgn-/0-fibroblasts enhances proliferation of WT and bgn-/0-
fibroblasts 
Proliferation on bgn-/0-cell derived ECM enhanced WT-cell growth two fold over control on 
plastic and diminished the difference between bgn-/0-fibroblasts and WT. mean ± SEM; n =4; *, 
p<0.05 WT-  versus bgn-/0-fibroblasts ; # p<0.05 plastic versus bgn-/0-ECM 
 
As shown in figure 3-8, pre-coating culture dishes with bgn-/0-fibroblast derived 
ECM as growth substrate, enhanced proliferation remarkably 48 h after plating. 
For these experiments two different explant isolations per genotype were used 
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for ECM production and each ECM was populated with two independent explant 
isolations per genotype. ECM produced by bgn-/0-fibroblasts enhanced 
proliferation of WT-fibroblasts 2.1 fold higher as compared to WT-control on 
plastic. The ECM produced by bgn-/0-fibroblasts induced proliferation of bgn-/0-
fibroblasts only 1.4 fold higher compared to proliferation on plastic. The WT-
ECM lacking biglycan diminished the difference in proliferation between the two 
genotypes, by increasing WT proliferation. 
To investigate if increased proliferation on bgn-/0-fibroblast derived ECM was 
due to a lack of biglycan, the proliferation on WT-derived ECM was analyzed in 
an identical approach. In this set of experiments, using WT cell-derived ECM, 
the proliferation of WT-fibroblasts was induced 1.8 fold over WT proliferation on 
plastic. Of note, WT-ECM inhibited the proliferation of bgn-/0-fibroblasts, 
suggesting that the lack of biglycan was indeed responsible for the proliferative 
phenotype. On WT-ECM bgn-/0-fibroblasts grew slower than on plastic and even 
slower than WT -fibroblasts that were stimulated by the pre-existing ECM. 
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Figure 3-9 WT-ECM enhances WT-fibroblasts but inhibits bgn-/0-fibroblasts 
WT-ECM enhanced the proliferation of WT-fibroblasts to a higher degree than that of bgn-/0-
fibroblasts. mean ± SEM; n =4; *, p<0.05 WT- versus bgn-/0-fibroblasts ; # p<0.05 plastic versus 
WT-ECM 
 
These experiments using a cell-derived ECM as growth substrate revealed that 
a WT-ECM increased the proliferation of WT-fibroblasts and abolished the 
proliferation benefit of bgn-/0-fibroblasts. Interestingly, the WT-ECM did not 
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stimulate WT-fibroblasts to the same extent as the bgn-/0-ECM. These data 
support the hypothesis that a bgn-/0-ECM provide a strong pro-proliferative 
benefit. 
 
3.2.2 Overexpression of murine biglycan protein reverts pro-
proliferative phenotype of bgn-/0-fibroblasts  
 
To rescue the phenotype by restoring biglycan expression, a lentivirus leading 
to biglycan overexpression was used. Therefore the murine biglycan mRNA was 
used as template from C57BL/6J WT mice. The construct was sequenced and 
reached 100 % sequence homology with the database sequence on NCBI Gene 
(NM_007542.4).  
 
Figure 3-10 Lentiviral restoration of biglycan expression in bgn-/0-fibroblasts 
DEAE isolated proteoglycans from 1 ml of 4 days conditioned cell culture supernatants were 
subjected to chondroitinase ABC digestion to remove GAG chains from core protein. BGN-
overexpression vector increased biglycan protein in supernatant conditioned by WT-fibroblasts. 
No core protein was detected in pCL1 mock transfected bgn-/0-fibroblasts. Overexpression 
vector restored biglycan expression in bgn-/0-fibroblasts. 
 
Transfected fibroblasts were plated at 5000 cells / cm² and grown in 10 % 
serum for 72 hours. Afterwards cells were counted in a hematocytometer. The 
virus treatment slowed down cell growth but the proliferative benefit of bgn-/0-
fibroblasts remained constant. Over expressing biglycan protein in the bgn-/0-
fibroblasts abrogated the proliferation benefit. 
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Figure 3-11 Lentiviral overexpression of biglycan protein abrogates the pro-proliferative 
phenotype of the bgn-/0-fibroblasts. 
Fibroblasts separated from explant cultures were transfected with lentiviral vectors. After seven 
days, fibroblasts were plated on new culture plates and the cell growth was determined 72 h 
after plating. WT -fibroblasts transfected with the empty mock vector pCL1 grew more slowly 
than bgn-/0-fibroblasts transduced with pCL1 control vector (black bar). Bgn-/0-fibroblasts 
transfected with biglycan (BGN-OE) vector were inhibited compared to bgn-/0pCL1 and 
resembled to WT pCL1. mean ± SEM; n = 5;* ,p<0.05 WT- versus bgn-/0-fibroblasts both pCL1 
transfected #; p<0.05 bgn-/0pCL1 versus bgn-/0BGN-OE 
 
 
3.3 Oil-supported collagen retraction (OSCR) assay revealed strong 
contractile phenotype of bgn-/0-fibroblasts 
 
The ability of cells to interact with and contract a collagen ECM is part of a 
physiological process referred to as traction. In addition, it is well known that 
myofibroblasts are a more contractile cell type than normal fibroblasts. We 
performed the oil-supported collagen retraction (OSCR) -assay according to 
Vernon and Gooden with some adaptations. The gels contained 1.25 mg/ml 
collagen and 15 x 103 cells per gel and were allowed to polymerize for two 
hours at 37°C. The gel contraction was documented 2 4 hours afterwards. 
Unpopulated control gels were used as standard for polymerization. The 
contraction of gels populated with WT- or bgn-/0-fibroblasts was calculated as 
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percentage of the cell-free unpopulated control gels.Gels populated with WT-
fibroblasts showed a contraction of 55.4 %. Bgn-/0-fibroblasts showed a 
significantly stronger contraction of 68.6%. 
 
Figure 3-12 OSCR-assay revealed significantly stronger contractile abilities of bgn-/0-
fibroblasts. 
Statistical analysis of OSCR-assay showed significantly increased contraction of collagen gels 
by bgn-/0-fibroblasts (black bar, last image of contracted gels) compared to WT-fibroblasts (white 
bar second gel in the middle of original images), mean ± SEM *;p<0.05; n=4  
 
Because stronger contractile abilities of myofibroblasts are a characteristic 
distinguishing these specialized cells from normal fibroblasts (20), the 
hypothesis was developed that bgn-/0-fibroblasts undergo un-stimulated  
spontaneous differentiation into myofibroblasts. 
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3.4 Immunocytochemical analysis of bgn-/0-fibroblasts phenotype 
 
To investigate the differences that cause the varying behaviour of the bgn-/0-
fibroblasts as compared to WT-fibroblasts, the expression of ECM molecules 
and components of cytoskeleton as well as focal adhesions were visualized by 
immunocytochemical staining with specific antibodies. Actin stress fibres are 
commonly stained with fluorochrome-conjugated phalloidin that binds directly to 
F-actin fibres in the cytoplasm.   
 
 
Figure 3-13 F-actin staining shows dramatic differences in the cytoskeleton of bgn-/0-
fibroblasts. 
Fibroblasts of the first passage from both genotypes (WT and bgn-/0) were stained for F-actin 
using phalloidin-FITC 24 h after plating. (A) In WT-fibroblasts fluorescent signal from phalloidin-
FITC (in green) was limited to cortical sites at the plasmamembrane where actin-filaments are 
connected to membrane complexes like for example focal adhesions and cadherin clusters. 
Nuclear counterstaining was performed using Hoechst 3320 dye. (B) In bgn-/0-fibroblasts F-actin 
stress fibres are thicker and stretch through the whole cell. Representative images are shown at 
200 fold magnification. 
 
It became obvious that bgn-/0-fibroblasts had a denser F-actin cytoskeleton than 
WT-fibroblasts. In WT-fibroblasts the phalloidin signal mostly came from areas 
close to the cell membrane, where actin filaments end up close to focal 
adhesions. These so called cortical complexes at the plasma membrane serve 
as cell-matrix connecting points or more precisely as link between cytoskeleton 
and the ECM. In contrast to WT-fibroblasts, bgn-/0-fibroblasts exhibit strong 
signals from filaments that were stretched through the whole cell, accumulating 
to dense bundles at the membrane. These findings suggested that differences 
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in the differentiation grade of bgn-/0-fibroblasts could be responsible for the 
increased proliferation response.  
The most common differentiation for fibroblasts is the transition into 
myofibroblasts, which is well characterized by incorporation of de novo 
synthesized α-smooth muscle actin (α-SMA) into stress fibres. This 
differentiation correlates with a higher expression of ECM components like 
collagens (e.g. collagen type I and collagen type VI), tropoelastin, the fibronectin 
fragment ED-A, focal adhesions, cadherins and stronger contractile abilities.  
The analysed marker proteins, α-SMA, fibronectin ED-A and tropoelastin were 
increased in bgn-/0-fibroblasts as shown in figure 3-13. This confirmed the 
hypothesis that bgn-/0-fibroblasts might directly differentiate into myofibroblasts 
in cell culture. 
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Figure 3-14 Immunocytochemical staining of differentiation marker α-SMA and 
differentiation-associated fibronectin fragment ED-A and tropoelastin. 
Immunocytochemical characterization of WT-fibroblasts (A, C, E) compared to bgn-/0-fibroblasts 
(B, D, F). Shown are representative images of staining for α-SMA (A and B), fibronectin ED-A 
(C, D) and tropoelastin (E, F) 24 h after plating. Bgn-/0-fibroblasts show strong accumulation of 
myofibroblast markers, as WT-fibroblasts only show basal expression of these proteins. (A, B) 
are at 200 x and (C-F) 100 x magnification. 
 
To further validate this thesis focal adhesion protein paxillin was stained 
immunocytochemically. This revealed another characteristic feature of 
myofibroblast differentiation in bgn-/0-fibroblasts, which had more signals from 
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anti-paxillin staining than WT-fibroblasts, representing increased establishment 
of focal adhesions. 
 
Figure 3-15 Representative Images of immunocytochemical staining for paxillin 
Anti-paxillin staining showed less signals for paxillin in WT (A) compared to bgn-/0-fibroblasts 
(B). More paxillin signals in immunolocalisation indicate increased numbers of focal adhesion 
complexes in bgn-/0-fibroblasts. 200 x magnification 
 
There are three filament systems in eukaryotic cells, the microfilaments which 
contain actins, the intermediate filaments (vimentin, desmin, lamin) and the 
microtubules composed of tubulins. While increased and differential expression 
of microfilaments and intermediate filaments mark the differentiation towards 
myofibroblast, the physiological role of microtubules during differentiation is 
largely unknown. 
The immunohistochemical analysis of bgn-/0-fibroblasts showed that 
microtubules are differentially regulated as well between the two genotypes. 
 
WT bgn-/0A B
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Figure 3-16 Representative images of immunocytochemical staining for β-tubulin 
Anti-β-tubulin immunodetection showed stronger signals for β-tubulin in bgn-/0-fibroblasts as 
compared to WT-fibroblasts. The microtubules in bgn-/0-fibroblasts are considerable thicker and 
more prominent compared to microtubules in WT-fibroblasts. 200 x magnification.  
Results 
 
 
 
50
3.5 Biochemical and molecular comparison of bgn-/0-fibroblasts to WT-
fibroblasts 
 
Furthermore, protein expression and mRNA levels of certain markers of 
myofibroblast differentiation were analysed, to characterize the differences 
between bgn-/0-fibroblasts and WT-fibroblasts more precisely. 
A detailed analysis of protein expression and mRNA expression was performed 
to further prove the differentiation into myofibroblasts and point out the different 
aspects of the phenotype caused by the absence of biglycan. First, the 
hypothesis that bgn-/0-fibroblasts differentiate into myofibroblasts was verified by 
α-SMA expression analysis.  
 
 
Figure 3-17 α-SMA mRNA and protein are increased in bgn-/0-fibroblasts. 
(A) The mRNA expression as well as (B) protein of α-SMA determined by real-time-RT-PCR 
and western blotting, are elevated in bgn-/0-fibroblasts. (B) upper panel HSP90 as loading 
control and lower panel α-SMA protein in bgn-/0- and WT-fibroblasts; mean ± SEM; *, p<0.05; 
n=5 
 
The analysis of α-SMA revealed that WT-fibroblasts only express little amounts 
of α-SMA mRNA and protein, while both m-RNA and protein of α-SMA are 
increased of about 2.5 fold in bgn-/0-fibroblasts, proving a differentiation into 
active myofibroblasts.  It was demonstrated that the pro-proliferative phenotype 
of bgn-/0-fibroblasts could be rescued by lentiviral-mediated restoration of 
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biglycan expression. To analyse if the high expression of α-SMA in bgn-/0-
fibroblasts could be reversed by overexpression of biglycan protein too, the 
protein level of α-SMA in pCL1 and BGN-OE transduced cells was analysed by 
western blotting.  
 
Figure 3-18 Overexpression of bgn does not reduce α-SMA protein in bgn-/0fibroblasts 
The protein level for α-SMA in WT and bgn-/0-fibroblasts 7 days after transfection with pCL1 
mock vector, or BGN-overexpression (OE) vector was determined by western blot. In the upper 
panel HSP90 is shown as loading control. α-SMA protein in WT- and bgn-/0fibroblsts is shown in 
the lower panel. α-SMA protein was quantified for statistical analysis using a Two-Way-ANOVA 
of variances; mean ± SEM; *, p<0.05 WT- versus bgn-/0-fibroblasts; n=3 
 
Figure 3-18 shows that restoring the expression of biglycan in bgn-/0-fibroblasts 
did not reduce the amount of α-SMA in these cells. Thus the differentiation 
phenotype caused by biglycan deficiency was not rescued by lentiviral biglycan 
expression as was the proliferative phenotype. 
The accumulation of α-SMA is characteristic of the differentiation into 
myofibroblasts. Differentiated myofibroblasts are capable of remodelling the 
surrounding matrix. This remodelling of ECM is accompanied by expression of 
high levels of structural ECM molecules, but also by high expression of 
crosslinking and ECM degrading enzymes. Therefore, a small set of crosslinking 
and ECM degrading enzymes was analysed. 
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3.5.1 ECM crosslinking and degrading enzymes are differentially 
regulated in bgn-/0-fibroblasts compared to WT-fibroblasts 
 
ECM crosslinking enzymes like the pro-collagen-prolyl-oxidases (PLOD) are 
directed to different epitopes in structural components of the ECM such as 
collagen. These enzymes oxidate specific amino acids and facilitate bindings 
between aligned molecules, but their function is not limited to ECM stabilization. 
The tissue transglutaminases (tgm) 1 and 2 are supposed to play a role during 
apoptosis and cellular differentiation for example . 
 
Figure 3-19 Expression of ECM crosslinking enzymes was altered in bgn-/0-fibroblasts. 
The total mRNA from 10000 cells/cm² were collected 24 h after plating. The mRNA was 
transcribed into cDNA and used for real-time-RT-qPCR for pro-collagen prolyloxidase isoforms 1 
and 2 and tissue transglutaminase isoforms 1 and 2. mean ± SEM; n = 3; *, p<0.05 WT- versus 
bgn-/0-fibroblasts 
 
During cardiac remodelling de novo synthesis and crosslinking of ECM mark 
only one part of the process, degradation of ECM is the other part. As already 
mentioned crosslinking of ECM molecules stabilizes the ECM. But in order to 
establish a stable ECM after injury, the previously disrupted ECM has at least in 
part to be removed. ECM degradation is an important process that generates 
fragments that are capable of inducing signalling for example via integrins. Post 
infarct remodelling is characterised by production of ECM or scar tissue that has 
to adapt to a stronger wall pressure and a loss of cardiomyocytes. To achieve 
this both processes crosslinking and degradation have to take place. 
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ECM breakdown is mostly executed by matrix metalloproteinases. This family of 
enzymes includes far more than thirty members by now. In charge for collagen 
breakdown and fibronectin degradation only a small subset was analysed by 
real time RT-PCR to display the ECM degradation abilities of the primary 
cardiac fibroblasts, in the absence of biglycan. Only trends towards of different 
expressions were detectable, but the discovery that MMP1a is down while 
MMP9 and 13 are likely to be up-regulated, may hint towards different profiles of 
ECM degrading enzymes caused by these two different genotypes. 
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Figure 3-20 Expression of matrix metalloproteinases 1a, 3, 9 and 13 showed a trend 
towards differential regulation and in bgn-/0-fibroblasts compared to WT. 
The total mRNA from 10000 cells/cm² were collected 24 h after plating. The mRNA was 
transcribed into cDNA and used for realtime-RT-qPCR for matrix metalloproteinases 1a, mmp3, 
mmp9 and mmp13. mean ± SEM; n = 3; *, p<0.05 WT- versus bgn-/0-fibroblasts 
 
 
3.5.2 Induction of matrix receptors and cytoskeleton-membrane-
anchoring complex in bgn-/0-fibroblasts 
 
Molecules like the CD44 receptor (30) and the dystrophin associated protein 
complex (DAPC) (32) have been shown to interact with biglycan. CD44 is 
known to be involved and up-regulated in cardiac remodelling and myofibroblast 
differentiation (31,63), while the DAPC is expressed in cardiomyocytes and 
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myofibroblasts, but hardly detectable in normal fibroblasts (22,33). CD44 is also 
involved in focal adhesion establishment and influences the motility of 
fibroblasts. CD44 is discussed as a factor that is necessary for the recruitment 
of fibroblasts to sites of injury (39). 
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Figure 3-21 The expression of CD44 was significantly increased in bgn-/0-fibroblasts. 
The total mRNA from 10000 cells/cm² were collected 24 h after plating. And CD44 expression 
was analysed by realtime RT-PCR. mean ± SEM; n = 7- 5; *, p<0.05 WT- versus bgn-/0-
fibroblasts. 
 
It is well documented that CD44 is able to activate TGF-β signalling by MMP 
activation, which leads to TGF-β release from the ECM, where it is sequestered 
by biglycan and decorin (64). Furthermore, it is known that TGF-β is the most 
familiar inducer of myofibroblast differentiation (65). Up to now it has never been 
described that biglycan influences the expression of CD44. 
The DAPC is a mechano-transduction complex that connects the ECM and the 
cytoskeleton using integrins (66). Via this linkage the DAPC transduces 
mechanical force or traction from the cytoskeleton to the ECM. Furthermore the 
DAPC-integrin complex is involved in recognition of tension that is applied to the 
ECM. As myofibroblasts exhibit strong traction forces on the ECM as shown in 
figure 3-11, it was tested whether bgn-/0-fibroblasts express higher levels of 
DAPC. It is shown here for the first time that biglycan deficiency upregulated 
dystrophin as part of the DAPC.  
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Figure 3-22 The mRNA expression of dystrophin was significantly increased in bgn-/0-
fibroblasts 
The total mRNA from 10000 cells/cm² were collected 24 h after plating. And dystrophin 
expression was analysed by real-time RT-PCR. mean ± SEM; n = 7- 5; *, p<0.05 WT- versus 
bgn-/0-fibroblasts. 
 
 
3.5.3 Characterization of TGF-β system in bgn-/0-fibroblasts 
 
TGF-β activity is regulated by several mechanisms. Firstly the expression of 
TGF-β and its receptors can be regulated, secondly TGF-β is secreted as a pro-
peptide that has to be modified and dimerize to the mature TGF-β form. TGF-β 
when secreted can bind to a latency complex and this complex as well as the 
mature TGF-β can be sequestered into the ECM, for example upon binding to 
biglycan. Due to the variety of possible pathways to regulate TGF-β neither 
protein nor mRNA levels alone give sufficient information concerning the activity 
of TGF-β signalling system. Nevertheless unbound, free secreted TGF-β was 
analysed in cell culture supernatants by TGF-β ELISA, as well as the mRNA or 
TGF-β1 and TGF-βRII. 
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Figure 3-23 TGF-β receptor type II is strongly up-regulated, while TGF-β itself remains 
unchanged. 
(A) TGF-β 1 and (B) TGF-β Receptor Type II mRNA were analyzed by real-time RT-qPCR. 
(C)Endogenously secreted TGF-β of cell culture supernatants was analyzed by TGF-β ELISA. 
Supernatants were collected at 12 and 24 h after plating. Mean ± SEM; n = 3; *, p<0.05 WT- 
versus bgn-/0-fibroblasts. Mean ± SEM; n = 6-7; *, p<0.05 WT- versus bgn-/0-fibroblasts. 
 
The reduced levels of free TGF-β detected after 24 hours are possibly due to 
diminished secretion or enhanced sequestration to the ECM, more likely is the 
alternative that TGF-β may have been bound to its surface receptor in a higher 
extent. Consequently these early results encouraged the further investigation of 
the role of TGF-β in the bgn-/0-fibroblasts. 
 
 
3.6 The neutralization of TGF-β rescues the pro-proliferative phenotype 
and differentiation of bgn-/0-fibroblasts 
 
To facilitate the role of intrinsic TGF-β in the pro-proliferative, differentiated 
phenotype of bgn-/0-fibroblasts, the cells were grown in the presence of TGF-β 
neutralizing antibody. 
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Figure 3-24 The proliferation benefit of bgn-/0-fibroblasts was abolished by neutralizing 
endogenous TGF-β signalling  
Proliferation in response to treatment with a neutralizing antibody to TGF-β (0.5 µg/ml) or 
isotype IgG was determined 48 h after plating in the presence of the antibodies by counting cells 
in a hematocytometer. Mean ± SEM; n = 3; *, p<0.05 WT- versus bgn-/0-fibroblasts; #, p<0.05 
bgn-/0anti-TGF-β versus bgn-/0IgG treated 
 
These experiments clearly showed that the pro-proliferative phenotype of bgn-/0-
fibroblasts was due to endogenous TGF-β signalling, as neutralisation of 
endogenous TGF-β completely abolished the proliferation benefit of bgn-/0-
fibroblasts while the WT -fibroblasts were not affected at all.  
To analyse if the contractile phenotype and the alterations of the cytoskeleton 
were also caused by the endogenous TGF-β signalling the neutralizing antibody 
was also used in the OSCR-Assay and treated cells were analysed by 
immunocytochemistry with respect to α-SMA incorporation into stress fibres. 
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Figure 3-25 Contraction of collagen matrix is inhibited in the presence of neutralizing 
antibody to TGF-β 
Contraction after 24 h treatment with a neutralizing antibody to TGF-β (0.5 µg/ml) or isotype IgG 
was determined by image analysis. Mean ± SEM; n = 3; *, p<0.05 WT- versus bgn-/0-fibroblasts; 
#, p<0.05 bgn-/0anti-TGF-β versus bgn-/0IgG treated 
 
The contractile abilities of both genotypes were completely blocked in the 
OSCR-assay by TGF-β neutralisation, which shows that neutralising 
endogenous TGF-β not only abolishes the proliferation benefit, but the 
differentiation into myofibroblasts as well. 
This was also confirmed by immunocytochemical analysis shown in figure 3-25, 
which clearly showed that due to the neutralisation of endogenous TGF-β, bgn-
/0
-fibroblasts lost their ability to incorporate α-SMA into stress fibres. 
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Figure 3-26 bgn-/0-myofibroblast phenotype reverses by neutralizing endogenous TGF-β 
signalling. 
Representative images of immunocytochemical staining of α-SMA showing a slight reduction of 
cortical α-SMA in WT-fibroblasts (A, B) after 24 h treatment with the neutralizing anti TGF-β 
antibody (0.5 µg/ml; B, D) compared to the IgG isotype control (A, C). In bgn-/0-fibroblasts (C, D) 
treatment with the TGF-β neutralizing antibody led to a phenotypical reversion of myofibroblast 
characteristics by strong reduction of α-SMA (D). Representative images of n=4 experiments 
200 x magnification. 
 
 
3.7 TGF-β signalling in bgn-/0-fibroblasts 
 
TGF-β signalling is not limited to the canonical pathway of SMAD signalling. 
TGF-β can interact directly or indirectly by transactivation with various cell 
surface receptors that still have not been identified in total. TGF-β beside the 
canonical way can activate several cascades that include different signalling 
molecules and consequently lead to different cellular outcomes. It is commonly 
agreed that TGF-β signalling shows cross talk with WNT signalling, MAPK 
pathway including p38, the SAPK/JNK pathway and ERK. The classical 
canonical pathway involves the SMAD proteins. SMAD 2 and 3 are receptor-
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activated SMADs that become phosphorylated upon receptor activation and 
build a complex with the common SMAD4. This complex translocates into the 
nucleus and acts as a transcription factor. There was no difference in SMAD3 
phosphorylation, while SMAD2 was significantly stronger phosphorylated in bgn-
/0
-fibroblasts under normal conditions compared to WT-fibroblasts (fig. 3-26). 
 
Figure 3-27 SMAD signalling shows over-activity of TGF-β in the absence of biglycan 
limited to SMAD2 phosphorylation 
The phosphorylation of SMAD3 and SMAD2 (pSMAD) was detected in total lysates from 10000 
cells/cm² 24 h after plating under standard conditions. Phosphorylation was calculated as the 
quotient of the integrated intensity of total SMAD and phosphorylated SMAD. Mean ± SEM; n = 
5; 3; *, p<0.05 WT- versus bgn-/0-fibroblasts. 
 
These results demonstrate that despite missing differences in the TGF-β 
expression (fig.3-22), TGF-β signalling is highly activated and mediates 
signalling by enhanced phosphorylation of Smad2, which nicely correlates with 
increased expression of TGF-βRII in bgn-/0-fibroblasts and the myofibroblast 
phenotype.  
These western blots also showed that phosphorylated SMAD2 was degraded 
because multiple cleavage fragments that were absent in the WT protein lysates 
appeared during these experiments in bgn-/0-fibroblasts.  
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Figure 3-28 Additional bands detected by anti-phosphoSMAD2 antibody in lysates from 
bgn-/0-fibroblasts reflect increased phosphoSMAD2 degradation. 
In total lysates from WT- (white bar) and bgn-/0-fibroblasts (black bar) 24 hours after plating, 
phospho-SMAD2 antibody detects fragments of phosphorylated SMAD2, which are 
predominantly present in samples collected from bgn-/0-fibroblasts. Mean ± SEM; n = 4-5; *, 
p<0.05 WT-  versus bgn-/0-fibroblasts.  
 
Smad2 is degraded as a negative feedback of TGF-β signalling. This 
degradation of SMAD2 by the proteasome is initiated by ubiquitinilation of 
SMAD2 by E2-ubquitin ligase SMURF2. But it is also reported that Smurf2 upon 
binding to phosphorylated Smad2 first recruits transcription repressors like 
SNoN and Ski for degradation (40). To analyse this additional possibility by 
which the complex of Smurf2 and phospho-SMAD2 might actively induce 
signalling, the expression of SMURF2 was analysed by western blotting. 
 
Results 
 
 
 
62
 
Figure 3-29 SMURF 2 protein is significantly increased in bgn-/0-fibroblasts. 
SMURF2 was detected in total lysates from fibroblasts grown at a density of 10000 cells/cm² 
under standard conditions 24 h after plating. Mean ± SEM; n = 7; *, p<0.05 WT- versus bgn-/0-
fibroblasts. 
 
Another crucial factor that is induced by TGF-β signalling is SMAD7, which is a 
so called inhibitory SMAD protein. SMAD7 represses most of the TGF-β 
regulated cellular responses like proliferation and ECM production, but SMAD 7 
is required for TGF-β induced apoptosis, through its interaction with β-catenin. It 
stabilizes β-catenin in the cadherin complex. Furthermore, high levels of β-
catenin and SMAD7 can cause an increase in c-myc. Together with p53 those 
two are postulated to induce apoptosis (42). 
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Figure 3-30 SMAD 7 and β-catenin protein are increased in bgn-/0-fibroblasts. 
SMAD7 (A) and β-catenin (B) were detected in total lysates from fibroblasts grown at a density 
of 10000 cells/cm² under standard conditions 24 h after plating. Loading of equal protein 
amounts was visualized by detection of HSP90. Mean ± SEM; n =3-6; *, p<0.05 WT- versus 
bgn-/0-fibroblasts. 
 
According to literature TGF-β induced apoptosis is mediated via high expression 
levels of SMAD7 and β-catenin, which induce the expression of c-myc and p53. 
Because both molecules are increased in bgn-/0-fibroblasts it was examined if 
bgn-/0-fibroblasts undergo apoptosis under standard conditions. 
Indeed it was detected that PARP 1 cleavage as well as Caspase3 cleavage 
were increased in bgn-/0-fibroblasts. 
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Figure 3-31 Increased cleavage of PARP 1 points towards pro-apoptotic phenotype of 
bgn-/0-fibroblasts in response to over-active TGF-β signalling. 
PARP1 and cleavage of PARP1 was detected in total lysates from fibroblasts grown at a density 
of 10000 cells/cm² under standard conditions 24 h after plating. Mean ± SEM; n =9; *, p<0.05 
WT- versus bgn-/0-fibroblasts. 
 
Therefore the current data may suggest that the enhanced endogenous TGF-β 
signalling that leads to differentiation of cardiac fibroblasts into myofibroblasts is 
in turn subsequently accompanied by increased apoptosis of myofibroblasts. 
 
 
3.8  Translation of in vitro results to post infarct remodelling in vivo. 
In vitro findings often do not correlate with the in vivo situation. To verify the 
relevance of this in vitro data it was a necessity to analyse if the biglycan knock 
out leads to enhanced myofibroblast differentiation after myocardial infarction in 
vivo as well. In post infarction remodelling TGF-β and biglycan are both up-
regulated. While TGF-β is an early phase responding gene, biglycan expression 
is induced at the late phase after myocardial infarction (52,67).  
The basal mRNA expression of α-SMA in heart was contributed by smooth 
muscle cells of coronary arteries and a few active interstitial myofibroblasts. It is 
of note, that the basal expression of α-SMA in bgn-/0-fibroblasts was already 
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elevated, which points towards already active myofibroblasts, because bgn-/0-
mice show no increased vascularisation of the heart. 
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Figure 3-32 Basal α-SMA mRNA expression in cardiac apex cordis of bgn-/0-mice is 
significantly increased.  
The mRNA of α-SMA is dramatically increased in 1 mm cardiac apex cordis samples from sham 
bgn-/0-mice compared to age matched littermate WT-mice. Mean ± SEM; n =5; *, p<0.05 WT- 
versus bgn-/0-mice. 
 
After myocardial infarction the expression of α-SMA increases, this is caused by 
increasing myofibroblast differentiation. This effect can be a first approach to 
examine myofibroblast differentiation and the amount of these cells. The basal 
levels of α-SMA mRNA was quantified in the cardiac apex cordis of twelve 
weeks old sham mice. The result shown in fig. 3-31 demonstrates that in bgn-/0-
hearts the expression of α-SMA is already increased, which suggests that 
fibroblasts are spontaneously differentiated into myofibroblasts in uninjured bgn-
/0
-hearts as well. 
Subsequently the expression of α-SMA mRNA in infarcted hearts was analysed. 
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Figure 3-33 In response to experimental myocardial infarction the α-SMA mRNA 
expression in cardiac apex cordis was increased and remained elevated in bgn-/0-hearts 
at days 3 and 7 after MI.  
Apex cordis from sham and post infarction hearts were lysed for total RNA extraction. mRNA 
was transcribed into cDNA and analyzed in real time RT-PCR for quantification of α-SMA  
expression. Mean ± SEM; n = 4-9; *, p<0.05 WT- versus bgn-/0-fibroblasts. 
 
The mRNA expression of α-SMA increased in response to MI. At day three after 
MI the signal in WT hearts was most prominent. The amount of α-SMA mRNA 
decreased thereafter but persisted elevated towards the late time point of 21 
days after infarction. In WT-hearts the amount of myofibroblasts at day 21 was 
already decreased by nearly 40 % of the amount at day 3. In bgn-/0-hearts the 
presence of myofibroblasts from day 3 declines by about 32 % to day 21 after 
MI. Therefore the rate of myofibroblast clearance seemed to be unaffected 
 
The increase of the mRNA always precedes the appearance of the protein. 
Immunohistochemical staining of α-SMA in murine MI was performed to answer 
the question if myofibroblasts or angiogenesis induce the high levels of α-SMA 
mRNA. At day 3 after MI only a few positive cells were detected as can be seen 
in figure 3-33. The immunolocalization of α-SMA within the infarct showed a 
distinct localization of α-SMA positive cells in coronary vessels and non-myocyte 
cells. 
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Figure 3-34 Immunohistochemical staining showed higher accumulation of α-SMA 
positive fibroblasts in the peri-infarct zone 3 days after MI 
Representative images of immunohistochemical staining of α-SMA demonstrating the 
appearance of myofibroblasts in the peri-infarct zone 3 days post MI with more α-SMA positive 
cells not located to vessels in bgn-/0-hearts compared to WT littermates. Arrows indicate α-SMA 
positive myofibroblasts. 
 
For day 7 after experimental MI these α-SMA positive cells were quantified in a 
defined area of 90000 µm², beginning at the fibrotic border to the infarct. 
Vessels were excluded from analysis.  
 
 
Figure 3-35 Immunohistochemical staining showed increased accumulation of α-SMA 
positive fibroblasts in the peri-infarct zone at 7 days post MI 
(A) Quantification of positively stained cells within 90000 µm² of the infarct border. Mean ± SEM; 
n =4-9; *, p<0.05 WT- versus bgn-/0-fibroblasts. (B, C) Representative images of 
immunohistochemical staining of α-SMA displaying active myofibroblasts in the peri-infarct zone 
7 days post MI with more positive cells in bgn-/0-hearts (C) as compared to WT-hearts (B).  
 
The analysis of the infarcted hearts revealed that there were more α-SMA 
positive myofibroblasts at day 7 after MI than at day 3. Furthermore it became 
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obvious that there were significantly increased amounts of α-SMA positive cells 
in infarcts from bgn-/0-mice at both time points. These data suggest that the in 
vitro results may be relevant for the post infarct remodelling in vivo, revealing 
that due to biglycan-deficiency more fibroblasts differentiate into myofibroblasts 
in the scar. As this may lead to extra tensions within the scar, this might 
contribute to rupture of the infarcted ventricle as described before (52). 
 
 
3.8.1 Bgn-/0-myofibroblasts fail to activate nNOS despite DAPC 
up-regulation in vivo after experimental MI 
 
The question remains, if there is a link between biglycan and a possible 
characteristic functional marker for myofibroblasts in vivo. The detection of 
increased dystrophin expression in bgn-/0-fibroblasts is described here as one 
hallmark for the differentiation in vitro. Immunohistochemical staining for 
dystrophin in post infarct hearts of WT and bgn-/0-mice revealed a surprising 
result. In the heart of bgn-/0-mice, cardiomyocytes showed stronger signals for 
dystrophin in their plasma membrane. In addition cardiac myofibroblasts in the 
infarct express dystrophin too.  
These dystrophin positive fibroblasts appear in the same amount as the α-SMA 
positive myofibroblast. In direct comparison it became obvious that in bgn-/0-
mice the signal for dystrophin-positive fibroblasts was dramatically increased 
showing a similar pattern as the α-SMA positive myofibroblasts. 
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Figure 3-36 The immunolocalization of dystrophin in the infarcted area shows 
dramatically increased numbers of dystrophin in bgn-/0-hearts after experimental 
myocardial infarction 
(A) Quantification of 90000 µm² of the infarct border. Positively stained cells were determined as 
percentage of total area and given as area fraction. Mean ± SEM; n =4-9; *, p<0.05 WT- versus 
bgn-/0-mice. Representative images of immunohistochemical staining of dystrophin demonstrate 
stronger signals in bgn-/0-fibroblasts compared to WT littermates. (B, D)Pictures were taken at 
40 x magnification and (C, E) 100 x magnification. 
 
To verify these immunohistochemical results the mRNA expression of 
dystrophin in apex cordis samples from mice that were subjected to 
experimental MI was analysed. It could be shown that, while dystrophin mRNA 
was elevated in response to the infarction in WT-mice, it was even more 
increased in bgn-/0-mice. 
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Figure 3-37 Dystrophin mRNA was increased in response to myocardial infarction and 
even more elevated to in bgn-/0-mice comp 
Apex cordis from sham and post infarct hearts were lysed for RNA extraction. RNA was 
transcribed into cDNA and analyzed by real time RT-PCR for quantification of dystrophin mRNA 
expression. Mean ± SEM; n =4-9; *, p<0.05 WT- versus bgn-/0--mice. 
 
It has been reported that biglycan influences the expression of syntrophins 
which represent the cytosolic components of the DAPC (32). Among the 
biglycan regulated proteins is α-syntrophin, which is up-regulated in bgn-/0-mice 
(fig. 3-37). Syntrophin is a linking protein that binds physically to dystrophin and 
the inducible nNOS.  
This link is important for mechanic tension response and the activation of nNOS. 
NO leads to vasodilatation NO that secures sufficient blood and oxygen supply 
of muscle. Correlating with the increased α-SMA and the dystrophin mRNA in 
the absence of biglycan the expression of α-syntrophin are up-regulated too, in 
response to MI. However, α-syntrophin mRNA declines after day 3 and 
decreases to the same level that was detected in WT-hearts.  
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Figure 3-38 Syntrophin mRNA was increased in response to myocardial infarction and 
even more elevated in bgn-/0-mice compared to WT littermates.  
Apex cordis from sham and post-infarct hearts were lysed for total RNA extraction. The mRNA 
was transcribed into cDNA and analyzed by real time RT-PCR for the quantification of α-
syntrophin mRNA expression. Mean ± SEM; n =4-9; *, p<0.05 WT- versus bgn-/0-mice. 
 
To analyse the nNOS expression in response to MI may give information about 
the functionality of the DAPC. The inducible isoform nNOS is highly up-
regulated in response to MI in WT-hearts at day 3. However the induction of 
nNOS expression in bgn-/0-hearts is significantly. 
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Figure 3-39 Post infarction induction of nNOS mRNA is significantly reduced in bgn-/0-
mice. 
Apex cordis from sham and post infarct hearts were lysed for total RNA extraction. The mRNA 
was transcribed into cDNA and analysed by real time RT-PCR for the expression of nNOS 
mRNA. Mean ± SEM; n = 4-9; *, p<0.05 WT- versus bgn-/0-mice. 
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These data may suggest that in bgn-/0-mice nNOS activation fails, at day three 
after MI. The physiological consequence of less vasodilatory NO in the infarcted 
heart may lead to critically reduced supply of oxygen. This may subsequently 
support impaired hemodynamics and infarct healing as seen in bgn-/0-mice after 
experimental myocardial infarction. Further functional analysis of infarcted 
hearts would be necessary to prove these mechanistic details. 
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4 Discussion 
 
Fibroblasts are cells of mesenchymal origin that produce a variety of ECM 
molecules including multiple collagens and fibronectin. To identify fibroblasts the 
examination of the morphology is still the gold standard. But the morphology can 
vary depending on the tissue origin or even with the location within the same 
organ. Fibroblasts are the main non-myocyte cell type in the heart, along with 
endothelial and vascular smooth muscle cells. Morphologically fibroblasts are 
flat and spindle shaped. A defining characteristic is that fibroblasts lack a 
basement membrane and this attribute can be used to distinguish fibroblasts 
from all other permanent cell types in the heart. Fibroblasts are source and 
target of different stimuli, with the task to coordinate chemical, mechanical and 
electrical signals between the cellular components and the ECM within the 
heart. It has been shown that upon stimulation cardiac fibroblasts secrete high 
amounts of ECM molecules including the small leucine-rich repeat proteoglycan 
biglycan (54,68). Biglycan is involved in collagen and elastin fibrillogenesis (34-
36). 
Furthermore in response to myocardial infarction biglycan (bgn) as well as the 
highly homologous decorin have been shown to be regulated differently. The 
genetic deletion of decorin led to increased scar size, higher remote hypertrophy 
and ventricular dilation. This phenotype was marked by collagen fibril disorder 
and a depressed ventricular function and suggested a role of decorin in proper 
fibrotic evolution of myocardial infarctions (51). The genetic deletion of biglycan 
caused an even more pronounced cardiac phenotype, characterized by 
dramatically increased mortality of bgn-/0-mice after experimental myocardial 
infarction, accompanied by perturbed scar remodelling and hemodynamic 
insufficiency (52). Mechanistically it was demonstrated that the collagen network 
of the infarct scars was distorted explaining the rupture phenotype. In the 
present study it was examined whether the loss of biglycan might affect the 
phenotype of cardiac fibroblasts in vitro which could cause the phenotype after 
MI in vivo. 
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4.1 Morphological differences between WT and bgn-/0-fibroblasts 
 
Primary cardiac fibroblasts from WT-mice show a uniform morphology of flat 
even shaped cells that remained constant through five passages in cell culture. 
These WT cells were relatively robust also with respect to the. During a two 
week period of treatment with high serum and bFGF cardiac fibroblast grew out 
from heart piece explants. To compare WT-fibroblasts to bgn-/0-fibroblasts, 
explants of both genotypes were isolated simultaneously. Bgn-/0-fibroblasts were 
smaller in size and showed a more rounded cell shape with thin protrusions 
(fig.3-1). Bgn-/0-fibroblasts grew out in considerable numbers already three days 
after explantation and could be harvested in higher numbers compared to WT-
fibroblasts (fig. 3-4).  
 
 
4.2 Pro-proliferative phenotype of cardiac fibroblasts in the absence of 
biglycan 
 
In the first set of experiments a pro-proliferative phenotype of biglycan deficient 
(bgn-/0) -fibroblasts was be detected. Bgn-/0-fibroblasts grew out from explant 
culture of hearts in significantly larger numbers compared to WT-fibroblasts. 
This period may represent a mixture of migratory and proliferative response. 
The pro-proliferative phenotype of the bgn-/0-fibroblasts was confirmed by 
thymidine incorporation and cell counting experiments (fig. 3-6, 3-7). 
The pro-proliferative phenotype was rescued either by providing fibroblasts with 
biglycan containing ECM as growth substrate or by lentiviral restoration of 
biglycan expression. In contrast to the presented data it was shown before that 
biglycan overexpression increases proliferation of smooth muscle cells in the 
aortic wall and in renal arterioles, proven by large numbers of PCNA-positive 
cells in these vessels and accompanied by an increase in the medial thickness 
of the vessels. As mechanisms were explained by an increased expression of 
cyclin dependent kinase (cdk) 2 and a reduction of cdk-inhibitor p27 (55) was 
proposed. 
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Some studies on proliferative responses to biglycan were executed by treatment 
with soluble biglycan. It is of interest, that soluble biglycan has different 
functions than ECM bound biglycan. Nevertheless, these studies showed that 
biglycan stimulates proliferation of microglial cells (69) and of rat osteoblasts 
from calvaria but not of human osteoblasts from the knee (70). It was published 
that biglycan inhibits proliferation and migration of endothelial cells, osteogenic 
precursors and pancreatic cancer cells (71). Apart from that, it was 
demonstrated that biglycan increases the expression of a cdk-inhibitor, namely 
p21. 
These studies show that biglycan has cell type specific effects on proliferation 
response. Additionally, it was published that biglycan has anti-proliferative 
effects in mesangial cells, that are dependent on PDGF-BB treatment (72). 
Therefore it is believed that biglycan has a regulatory function with respect to 
the cyclin- dependent kinases and their inhibitors and might thereby control cell 
cycle progression. Furthermore biglycan and the class II SLRP lumican inhibit 
the expression of cyclin A and elevate the cell cycle inhibitors p21/p27 (47,73).  
Another pathway how biglycan regulates cell growth is the physical interaction 
with growth factors. It has been shown that growth factors that activate biglycan 
expression afterwards are targets of biglycan mediated inhibition such as TGF-
β. Furthermore, biglycan acts also as an important part of regulatory feedback 
loops for PDGF-BB as well as for TNF-α and TGF-β (72,74). 
 
 
4.3 Differentiation in the absence of biglycan 
 
The morphological analysis of bgn-/0-fibroblasts revealed distinct differences to 
WT-fibroblasts. The detailed immunohistochemical analysis of the fibroblasts 
proved that these differences already appear in the cytoskeleton. Bgn-/0-
fibroblasts were smaller in size and showed a dense α-SMA positive 
cytoskeleton, which is a characteristic feature of differentiated myofibroblasts 
(20). The restoration of biglycan expression by the lentivirally mediated 
overexpression rescued only the proliferative phenotype but did not rescue the 
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differentiation, as verified by α-SMA protein expression. Furthermore bgn-/0-
fibroblasts show stronger signals for the fibronectin ED-A fragment. This 
fibronectin splice variant is a ligand at α4β7-integrin and thereby connects cell 
membranes to ECM. Fibronectin ED-A is upregulated in various healing 
responses and disease states such as in skin granulation tissue and hepatic 
fibrosis (75). It was shown that this fibronectin ED-A domain is necessary for 
TGF-β triggered α-SMA expression and the differentiation into myofibroblasts 
(76). These results point towards multiple but in part independent actions of 
biglycan with affecting proliferation and myofibroblast differentiation. Both 
proliferation and differentiation come along with differences in the expression of 
the TGF-β receptor type II, which was increased in the absence of biglycan. 
Moreover the neutralisation of endogenous TGF-β resulted in the inhibition of 
proliferation and differentiation too. 
 
It is generally acknowledged that TGF-β is the priming factor that activates 
myofibroblasts. TGF-β is a growth factor that supports differentiation rather than 
proliferation. Upon activation of TGF-β, PDGF and connective tissue growth 
factor (CTGF, (77,78)) which are predominantly responsible for proliferation of 
myofibroblasts are induced. It was shown in vascular endothelial cells that by 
supporting an anti-proliferative effect of biglycan, CTGF suppresses its 
synthesis (79). Other soluble factors that have been shown to promote 
myofibroblast activation are angiotensin II, aldosterone, thrombin and endothelin 
(54,68,80-83). Angiotensin II stimulates TGF-β and also the expression of 
biglycan (68). After MI angiotensin II induces fibroblast proliferation in rats. 
Angiotensin II is detectable in every ventricle in the early phase from day 2 until 
day 4 after MI. It is also located at sites of myocyte necrosis and in the 
widespread peri-vascular area.  Through the induction of TGF- β angiotensin II 
induces the appearance of myofibroblasts from day 2 until week 6 after 
angiotensin II treatment (81).  
However, a variety of factors are involved in myofibroblast differentiation as well 
and these factors also affect biglycan expression even if only partly. Aldosterone 
infusion inhibits fibroblast proliferation after MI and leads to a deferred 
myofibroblast appearance. However it has not been investigated yet if 
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aldosterone has any effects on biglycan expression (81). Thrombin stimulates 
the biglycan expression in cardiac fibroblasts as well as in vascular smooth 
muscle cells and it also induces the differentiation of lung fibroblasts into 
myofibroblasts (54,80). Endothelin induces the differentiation of skin fibroblasts 
and keratinocytes into myofibroblasts (83).  It has been published, that 
endothelin induces biglycan expression in vascular smooth muscle cells by 
endothelin receptor transactivation of TGF-βRI (82). The mentioned studies 
agree that a factor that induces myofibroblast differentiation induces biglycan 
too. In summary many of the regulators of the myofibroblast phenotype involve 
effects on biglycan expression and TGF-β activity. The role of TGF-β  in 
differentiation is not an on/off mechanism but a delicately regulated process and 
depends on the cellular response to ECM remodelling (84). 
It has been shown that biglycan is involved in bone marrow stromal cell (BMSC) 
differentiation. In BMSC biglycan -deficiency represses the differentiation into 
osteogenic cells. In the same study it has also been shown that biglycan 
expression inhibits the proliferation of BMSC. This phenotype can be rescued by 
WISP 1, a growth factor of the CCN family administration to the cells (71).  
Biglycan-deficiency resulted in a higher phosphorylation of SMAD2 a regulatory 
SMAD.  
 
The presented data demonstrates that in the absence of biglycan, cardiac 
fibroblasts express higher levels of the TGF-βRII and that they show increased 
phosphorylation of the TGF-β signalling mediator SMAD2. The canonical 
pathway of TGF-β includes the activation of both r-SMADs, SMAD2 and 
SMAD3. As SMAD 3 phosphorylation was not increased in bgn-/0-fibroblasts, it 
was likely that TGF-β signalling was mediated by other signalling cascades. The 
increased phosphorylation of SMAD2 comes along with an increased 
expression of SMURF2. This coincidence of an increased phosphorylation of 
SMAD2 and an increased expression of SMURF2 suggests additional signalling 
pathways. Ubiquitin ligase SMURF 2 recruits SMAD2 for proteasomal 
degradation and it has also been described to build a complex with 
phosphorylated SMAD2 leading to the degradation of transcription inhibitors like 
SnoN and c-Ski (40). It has been shown recently that upon TGF-β treatment c-
Discussion 
 
 
 
78
Ski translocates into the nucleus in the long term. Overexpression of c-Ski in 
cardiac myofibroblasts leads to the loss of α-SMA and contractility and to the 
induction of apoptosis. Hence c-Ski is an example of a TGF-β responding factor 
that is involved in reversion of the myofibroblast phenotype. Additionally the 
expression of the inhibitory SMAD7 is increased in bgn-/0-fibroblasts. The 
inhibitory SMAD 7 is localized in the nucleus. Due to active TGF-β signalling 
SMAD7 translocates from the nucleus into the cytosol where it interacts with the 
kinases TAK1, MKK3 and p38. The activation of this pathway can also lead to 
the induction of the transcription factor nuclear factor kappa B (NFκB), a pro-
proliferative and pro-migratory factor, which is also increased in the absence of 
biglycan. Specific inhibitors to the single kinases could be used to verify their 
involvement in the signal transduction. Additionally the β-catenin expression 
was increased in bgn-/0-fibroblasts. An increased accumulation of β-catenin in 
the cytosol is well documented upon TGF-β stimulation. It was demonstrated 
that in the course of myofibroblast differentiation β-catenin interacts physically 
with SMAD2 during α3β1 integrin signalling. Due to its interaction with E-
cadherin/ β-catenin complex, α3β1 integrin locates at cell-cell contact sites. 
Cadherins are transmembrane proteins with extracellular calcium binding 
domains; these molecules connect cells at their surfaces by homodimerization 
of the extracellular domain following calcium binding. Cadherins bind to actin 
filaments and α- and β-catenin at the intracellular part. The loss of cadherins is 
an established diagnostic feature in pathological conditions, as it promotes 
tissue instability and invasiveness of for example tumor cells (85,86). 
Another linkage between TGF-β induced SMAD proteins and β-catenin is that β-
catenin is stabilized by SMAD7 at cadherin cell-cell adhesion sites. SMAD7 
prevents the ubiquitinylation and degradation of β-catenin. The accumulation of 
β-catenin can lead to active signalling, as β-catenin translocates into the 
nucleus and induces the transcription of genes associated with apoptosis. 
Furthermore SMAD7 interaction with β-catenin is required for TGF-β induced 
apoptosis (42-44).  
Additionally, it has been demonstrated that biglycan and fibromodulin double 
deficient mandibular condylar chondrocytes have an overactive TGF-β 
signalling, resulting in chondrogenesis and ECM turnover. The loss of biglycan 
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and fibromodulin leads to a reduced sequestration of TGF-β that causes an over 
activity of TGF-β (64). The effect of biglycan seems to be tissue- and cell type- 
specific. Biglycan as a calcium modifying molecule supposedly plays a different 
role in the heart than it does in bone marrow.  
 
The characteristic of ECM remodelling during infarct healing is the accumulation 
of collagen. The deposition of collagen is accompanied by increased 
pyridinoline cross-links, which are derived from hydroxylated lysine residues. 
The increase in pyridinoline crosslinks is likely to be the result of an increased 
activity of the enzyme that is responsible for the hydroxylation of the lysine 
residues in collagen peptides which are catalyzed by the procollagen-lysine, 2-
oxoglutarate 5-dioxygenases (PLOD) 1 and 2.  The resulting hydroxylysyl 
groups in collagen are attachment sites for carbohydrates and 
glycosaminoglycans and thus are crucial for the stability of intermolecular 
crosslinks. Collagen crosslinking is supposed to determine the miscellaneous 
relations that exists between accumulation of cardiac collagen and either 
myocardial stiffness or ventricular remodelling in hypertension (87). Thus the 
expression of collagen crosslinking enzymes gives information about the 
remodelling capacity within a tissue. In bgn-/0-fibroblasts PLOD1, PLOD2 were 
induced significantly as compared to WT-fibroblasts.  
Another group of crosslinking enzymes is respresented by the tissue 
transglutaminase (tgm) 1 and 2. While tgm1 is not influenced by the genetic loss 
of biglycan in cardiac fibroblasts, the tgm2 expression shows a strong trend 
towards induction. Numerous studies over the last two decades revealed 
multiple functions of tissue transglutaminase 2 (tgm2). It is of note that like 
biglycan, tgm2 has Ca2+-dependent functions leading to the transamidation of 
proteins and the formation of protein polymers via protease-resistant covalent 
isopeptide bonds. But Ca2+ binding happens at concentrations usually in the 
supraphysiological, not the physiological range that is associated with most 
intracellular processes. This means that they are virtually inactive under normal 
conditions and only activated following major disruptions in physiological 
homoeostatic mechanisms (88). Tgm2 also possesses GTPase enzymatic 
activity which connects this enzyme to intracellular signalling pathways. 
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Moreover, in addition to the cytoplasmic and nuclear localization, a significant 
part of tgm2 is present on the cell surface. A number of recent findings indicate 
that surface tgm2 is involved in the interactions of cells with the surrounding 
ECM. In epithelial cell attachment and cell spreading tgm2 appears to be 
concentrated at cell adhesion sites that are enriched with β1 integrin. In densely 
spread cell-layers tgm2 appears to be more diffusely distributed along the basal 
membrane, with dense localizations at sites of cell-cell and cell-substratum 
contacts (89,90). Tgm2 modifies the stability of ECM proteins and renders the 
ECM resistance to degradation. In addition, tgm2 also activates TGF-β. Both 
actions of tgm2 modulate the infiltration by macrophages and myofibroblasts 
(91).  It has been shown that in rats the ectopic expression of tgm2 increased 
the caspase-3 activity and calcium overload in cardiomyocytes (92). The 
induction of crosslinking enzymes in bgn-/0-fibroblasts was not confirmed in vivo, 
where only a trend towards induction could be detected (52). 
ECM remodelling is not only composed of ECM production and crosslinking, 
ECM degradation is also of major importance. The key players in this process of 
degradation are the matrix metalloproteinases.  
Interstitial collagenase (MMP-1), neutrophil collagenase (MMP-8), and 
collagenase-3 (MMP-13) possess high substrate specificities for fibrillar 
collagens, as well as other ECM proteins such as proteoglycans, including 
biglycan, perlecan and versican. Biglycan has shown to protect collagen fibres 
from MMP mediated degradation, while biglycan itself is degraded by MMP13 
during cartilage degradation (27). The gelatinases (MMP-2 and MMP-9) 
demonstrate a substrate affinity for denatured fibrillar collagen, basement 
membrane proteins such as collagen type IV, fibronectin, and laminin, but they 
exhibit a proteolytic activity against elastin and proteoglycans as well. The 
substrate selection for stromelysin-1 (MMP-3) includes proteoglycans, all 
basement membrane proteins and elastin. The expression and activity of MMPs 
after myocardial infarction influences the cardiac outcome as deletion of MMPs 
improves infarct healing and deletion of tissue inhibitors of MMPs (TIMPs) 
accelerate cardiac remodelling and exacerbates cardiac remodelling and heart 
failure (93-95). It was shown that the collagenases MMP8 and MMP13 are 
rigorously upregulated during the first five days following acute MI (96). 
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The induction of both ECM crosslinking and degrading enzymes is characteristic 
for the myofibroblastic phenotype and supports the thesis that bgn-/0-fibroblasts 
show distinct differences to WT-fibroblasts in respect to cardiac remodelling 
after MI. As reported before (52) these findings correlate with the increased 
expression of MMP13 in bgn-/0-mice after experimental MI in vivo. The 
discrepancy in the expression of crosslinking and degrading enzymes between 
in vitro and in vivo data might be due to the time point at which the data was 
collected. The in vivo data was collected at day 7 after experimental MI, when 
the scar is established and the myofibroblasts already start to disappear. 
However, the in vitro data mirrors a proceeding a situation where myofibroblasts 
are still highly active. 
 
The induction of CD44 expression in the absence of biglycan draws attention on 
new aspects, as CD44 is also involved in focal adhesion establishment and 
influences the motility of fibroblasts. CD44 is also supposed to be a factor that is 
necessary for the recruitment of fibroblasts to sites of injury (39). Interestingly 
CD44 activates TGF-β signalling by modulating MMP activation. This activation 
of MMPs leads to TGF-β release from the ECM, where it is sequestered by 
biglycan and decorin (64). The two gelatinases MMP-2 and MMP-9 
proteolytically cleave latent TGF-β, providing an important mechanism for TGF-
β activation. It has been published that CD44 recruits MMP-9 which then 
localizes to the surface of normal keratinocytes where it activates latent TGF-β. 
Therefore it may be suggested that coordinated CD44, MMP-9, and TGF-β 
function may provide a physiological mechanism of tissue remodelling in 
response to disease (97). In CD44 null mice fibroblast infiltration and matrix 
production in the infarct zone are markedly reduced, both supports the role of 
CD44 as a regulatory receptor for myofibroblast differentiation and infiltration 
(63). The up-regulation of CD44 in the absence of biglycan matches the 
differentiated phenotype of the bgn-/0-fibroblasts. Analysing bgn-/0-fibroblasts 
proliferation and differentiation under treatment with either a knock down by 
short-hairpin RNA to CD44 and MMP inhibitors could be utilized to prove this 
concept. In summary the absence of biglycan affects the TGF-β system 
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involving TGF-β sequestration, receptor expression, cytosolic signalling 
mediators as well as the cross talking between TGF-β and ECM receptors. 
 
Another surprising finding was the change in the expression of components of 
the dystrophin associated protein complex (DAPC) in bgn-/0-fibroblasts. For 
skeletal muscle, it was shown that biglycan physically interacts with the DAPC 
and regulates the expression of important components of this complex. It was 
also shown that biglycan is up-regulated in the dystrophic mdx (x-related 
muscular dystrophy) muscle. This brings up the idea that biglycan might also 
influence the DAPC in cardiac muscle in response to hypertrophy and fibrosis 
(98). 
 
 
Figure 4-1 The dystrophin associated protein complex induces NO release upon muscle 
contraction to provide muscle perfusion by blood vessel dilation. 
The dystrophin associated protein complex (DAPC) links the cytoskeleton to the structural 
components of the ECM. Tension and contraction are transduced by this multi-component 
complex. 
 
In this light, it is important to investigate the effects of biglycan deficiency on the 
DAPC in cardiac fibroblasts. This multi-component complex recruits the nNOS 
to the sarcolemma where the enzyme binds to syntrophins. The muscle 
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contraction is coupled to calcium influx which is directly associated with NO 
synthesis. The formation of NO at the muscle cell membrane by nNOS 
facilitates the directed diffusion of NO towards vascular smooth muscle cells. In 
vascular smooth muscle cells NO targets the guanylyl cyclase, whose activity is 
elevated about 100-fold due to the binding of NO. The resulting increase of 
cGMP mediates the vessel dilation and increases the perfusion of the 
contracting muscle. 
Biglycan regulates the expression of DAPC proteins like dystrobrevins, 
syntrophins and nNOS (32). The activation of nNOS leads to the secretion of 
vasodilatory NO which has been shown to induce the biglycan expression in the 
cardiac system (54) providing a regulatory feedback loop.  
It may be hypothesized that the induction of biglycan expression functions as a 
negative regulator of myofibroblast differentiation that is partly lost in bgn-/0-
fibroblasts due to enhanced TGF-β signalling. Furthermore the lack of biglycan 
might disturb the biological function of the DAPC, leading to a loss of function in 
bgn-/0-myofibroblasts. Figure 4-2 provides a schematic overview of these two 
working hypotheses.  
 
 
4.4 Constitutive rate of apoptosis in the absence of biglycan is part of 
unleashed TGF-β signalling 
 
Despite its functions concerning the regulation of proliferation and 
differentiation, biglycan influences apoptosis as well. This is another interesting 
point supporting the hypothesis that biglycan is critically involved in the 
regulation of the myofibroblastic response. 
Under standard conditions biglycan deficient fibroblasts show a high level of 
PARP 1 cleavage, which is indicative for increased apoptosis. These 
specialized cells, disappear from sites of injury after the establishment of healed 
tissue has been reached, by undergoing apoptosis (20). Therefore the down 
regulation of biglycan as observed in vivo during late phase remodelling of scar 
healing might contribute to apoptotic removal of fibroblasts. This is in line with 
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the observation in mesangial cells it has been shown that soluble biglycan 
inhibited cyclohexamid induced apoptosis (72).  
 
 
4-2Schematic summary of biglycan functions in WT and bgn-/0-fibroblasts 
The upper panel presents the WT-fibroblast growth and differentiation regulation in the presence 
of biglycan. Biglycan induces the cdk-inhibitor p21 and thereby inhibits the proliferation of 
fibroblasts. Biglycan is involved in the organisation of fibrillogenesis of collagen and elastic fibres 
and secures ECM integrity. Furthermore biglycan inhibits TGF-β and thus regulates 
myofibroblast differentiation and apoptosis in response to TGF-β.  In the knock out fibroblast 
(lower panel) the lack of biglycan leads to a pro-proliferative phenotype as the induction of the 
cdk inhibitors is absent. Additionally the absence of biglycan unleashes TGF-β signalling, 
leading to spontaneous differentiation into myofibroblasts. Bgn-/0-myofibroblasts lack the ability 
to organize the ECM. Moreover bgn-/0-myofibroblasts show deregulation of the DAPC, which 
might lead to alterations in calcium cycling and production of vasodilatory NO. At the end the 
lack of biglycan results in TGF-β induced apoptosis mediated by SMAD7 and β-catenin.   
 
In 2003 Young et al. firstly showed that biglycan deficient mice have diminished 
capacity to produce bone marrow stromal cells, and secondly that these cells 
also show a reduced response to TGF-β, reduced collagen synthesis and 
comparatively exhibit more apoptosis than cells from normal control littermates. 
Additionally, it has been demonstrated that biglycan and decorin double 
deficient BMSCs undergo apoptosis more often than WT BMSCs (99).  
Furthermore SMAD 7 interacts with β-catenin to modulate TGF-β-induced 
apoptosis. Thus SMAD7 acts as positive regulator of the TGF-β activated 
pathway involving TAK1-MKK3 and p38 mitogen-activated kinases, leading to 
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induction of c-myc and p53 and subsequently apoptosis (42,43,100,101). 
Indeed increased apoptosis indicated by PARP cleavage has been detected 
despite of the proliferative phenotype. These results suggest that biglycan is not 
only involved in appearance of myofibroblasts, but also in regulation of 
myofibroblast disappearance 
 
 
4.5 Translation of bgn function in vitro into in vivo situation 
 
To understand the complex pathological events after acute myocardial infarction 
(MI) it is useful to separate these events into functional phases. A useful division 
would contain the initial phase when the myocardium directly reacts on vessel 
occlusion induced hypoxia, the early phase subdivided into inflammatory and 
proliferative phase, when cardiac remodelling is crucial and the late phase when 
the healing is processed and adaptation to the injury has accomplished (62).  
The initial phase is also termed evolving phase and is timely restricted. During 
this phase hydrogen ions accumulate in the myocardium and potassium ions 
are extruded from the cells into extracellular space. Calcium2+ is replaced from 
the sarcoplasmic reticulum by contractile proteins like the DAPC. This leads to 
cease of contraction. Sodium ion influx leads to swelling of cells. Proteolytic 
enzymes are released into the ECM space and Ca2+ ultimately invades the 
mitochondria inducing apoptosis. Additionally necrosis of cardiomyocytes occurs 
during ischemia. Necrosis of cardiomyocytes leads to release of chemokines 
and cytokines for recruiting leukocytes to the ischemic area. But also the 
vasculature is affected, capillaries are compressed collateral vessels are 
compromised and leakiness of small capillaries convey the risk of haemorrhage 
(102). The following inflammatory phase is characterized by infiltration of the 
infarct area by macrophages, granulocytes and monocytes (103,104). During 
inflammation of the infarct vascular permeability leads to extravasations of 
plasma proteins leading to fibrin-based provisory scar (105). The accumulation 
of cytokines, chemokines and growth factors, such as TGF-β, lead to the 
appearance of activated myofibroblasts (23). During the proliferative phase of 
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infarct healing the fibrin-based scar is removed by granulation tissue cells and 
activated myofibroblasts proliferate and produce extensive amounts of ECM, 
establishing a cellular fibronectin-, hyaluronan- and collagen- based scar. 
Additionally fibroblasts and myofibroblast reorganize the microvasculature. 
During this phase of cardiac remodelling the composition of infarct ECM 
changes rapidly and dramatically alters microenvironment and thereby 
regulation of cell behaviour. Additionally the changes in ventricular ECM alter 
the mechanical properties of the ventricle and also modulate the cellular 
phenotype and gene expression profiles. Subsequently the late phase of infarct 
healing is characterized by a matured scar. During this phase myofibroblasts 
disappear from the infarct zone by apoptosis and probably by reversion into 
resident fibroblasts. If myofibroblasts disappear too early from sites of injury 
they would leave immature scars, but persistence in high numbers would lead to 
increasing fibrosis, which would cause a progressive heart failure (14, 16, and 
23). 
 Most importantly the myofibroblast phenotype of bgn-/0-fibroblasts appearing in 
vitro was also detected in vivo. Namely, increased α−SMA occurred in infarcted 
hearts of bgn-/0-mice at all day 3 and day 7after MI (fig. 3-33).  
Furthermore biglycan-deficiency may act pro-fibrotic by causing myofibroblast 
differentiation and in turn ECM production. Up to now there has been no 
evidence of a pro-fibrotic phenotype in bgn-/0-mice during in vivo experiments. 
Moreover the pro-apoptotic phenotype of the bgn-/0-myofibroblasts has to be 
taken into account too. The more myofibroblasts disappear early, possibly after 
a shortened life span, the less myofibroblasts are affecting proper tissue 
remodelling. Apart from that it is also possible that bgn-/0-myofibroblasts are 
physiologically less capable of ECM remodelling. Thus the suggestion that bgn-
/0
-myofibroblasts are not as active concerning their fibrotic response is more 
likely. Furthermore in WT-mice myofibroblasts disappear at the time point when 
biglycan massively accumulates in the peri-infarct area (fig.4-1), (52). All data 
considered this allows the assumption that biglycan acts as a molecular switch 
to terminate the myofibroblast response. 
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Figure 4-3 Timeline of functional events after myocardial infarction and the role of 
biglycan 
This schematic timeline presents functional events following acute myocardial infarction. Cardiac 
fibroblasts recruit macrophages to the infarcted tissue. During the first two days macrophages, 
granulocytes and monocytes infiltrate the infarct. Fibroblasts and macrophages secrete high 
amounts of cytokines and growth factors like TGF-β, which lead to the activation and 
differentiation of fibroblasts into myofibroblasts, that peak between day 3 and day 7 after MI. 
Myofibroblasts contract the infarct tissue and secrete ECM molecules, MMPs and additional 
enzymes to remodel the ECM. Upon remodelling a stable scar is formed by day 7. Biglycan is 
known to be involved in collagen and elastin organization and it is up-regulated during 
remodelling and scar formation, reaching a peak expression at 7 days after MI. At this time point 
myofibroblasts are already declining.  
  
The up-regulation of dystrophin and syntrophin after MI was apparently not a 
feature limited to cardiomyocytes, because myofibroblasts are positive for 
dystrophin too as shown by immunohistochemistry in this thesis. This data 
shows for the first time, which myofibroblasts express high amounts of 
dystrophin and syntrophin in the infarcted ventricle, both proteins are only 
negligibly detectable in normal fibroblasts. The similarity of α-SMA and 
dystrophin location in the infarct and the strong signal for dystrophin in 
fibroblastic cells, suggest the possibility that dystrophin might be a functional 
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marker for myofibroblasts in the heart. The DAPC is required for sarcolemmal 
localization of nNOS (106) and it is possible that the absence of biglycan the 
DAPC is deregulated and that thus the activation of the neuronal nitric oxide 
synthase (nNOS) after experimental MI fails (fig. 3-38). The nNOS knock out 
mice exhibit relatively normal heart function with a suppressed ionotropic 
response to β-adrenergic stimulation, which reflects changes in myocyte 
calcium cycling. As the eNOS/nNOS double deficient mice show a defect in 
calcium cycling that resembles the one of nNOS-knock out, it is assumed that 
the nNOS effect is predominant in the heart (107). Furthermore it was shown 
that nNOS-/--mice exhibit increased mortality and an impaired hemodynamic 
function after experimental myocardial infarction (108). The hypothesis that 
biglycan is involved in NO release from myofibroblasts still has to be verified by 
further experiments. 
In conclusion the presented data show that the SLRP biglycan, despite its role 
in stabilizing the collagen containing ECM and protecting it from cleavage, is 
involved in the signalling that mediates fibroblast differentiation and proliferation. 
This is of interest with respect to therapeutic pharmacological intervention since 
AT1-antagonists inhibit biglycan expression in cardiac fibroblasts and are known 
to reduce fibrosis (68,109). 
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5 Summary 
After myocardial infarction (MI) extracellular matrix (ECM) remodelling is on the 
one hand required for the formation of stable scar tissue but on the other hand 
can turn into pathologic remodelling. The small leucine-rich proteoglycan 
(SLRP) biglycan (bgn) has been shown to be critically involved in these 
processes. During post-ischemic remodelling cardiac fibroblasts differentiate 
into myofibroblasts which are the main cell type mediating ECM remodelling and 
scar contraction. Aim of the present study was to characterize the role of 
biglycan for the phenotype of cardiac fibroblasts.  
Cardiac fibroblasts were isolated from hearts of wild-type (WT) versus bgn-/0- 
mice. Phenotypical characterization of the bgn-/0-fibroblasts revealed increased 
proliferation that was suppressed to WT-level by WT-cell-derived ECM and by 
lentiviral restoration of biglycan expression. Characterization of bgn-/0-fibroblasts 
revealed increased expression levels of ECM crosslinking enzymes, as well as 
CD44 and TGF-βRII. In line with these results the phosphorylation of SMAD2 
and ERK1/2 was increased and administration of neutralizing antibodies to 
TGF-β reversed the pro-proliferative phenotype. Furthermore, bgn-/0-fibroblasts 
were characterized by increased alpha-smooth muscle actin (α-SMA) 
incorporated into stress fibres, increased expression of focal adhesions and 
increased contraction of collagen gels, indicative for differentiation into 
myofibroblasts. Surprisingly, bgn-/0-fibroblasts showed increased apoptosis 
under normal conditions. In vivo in WT-hearts the time course of α-SMA 
expression post MI showed peak levels at 3 days. Of note in bgn-/0-mice the 
increase of α-SMA was markedly enhanced suggesting that biglycan deficiency 
also promotes myofibroblast proliferation and differentiation in vivo post MI. For 
the first time it was shown that myofibroblast differentiation caused by biglycan 
deficiency was accompanied by increased expression of the dystrophin 
associated protein complex in vitro and additionally in vivo. Importantly an up-
regulation of the DAPC did not correlate with an induction of nNOS expression 
post infarction. This data support the hypothesis that bgn-/0-fibroblasts 
differentiate to myofibroblasts and exhibit characteristic features of this 
specialized cell type, but fail with respect to key functions, which results in 
apoptosis, impaired scar formation and disturbed hemodynamic function after 
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MI. In conclusion these data point to an inhibitory role of biglycan during cardiac 
myofibroblasts proliferation and differentiation possibly due to increased 
sensitivity to endogenous TGF-β and SMAD2 signalling. 
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